Module 5 — Master Protocol Index

Welcome + how to use this protocol library
Module 5 compound portfolio at a glance
Per-canonical protocols (9)
Adjunct protocols (3)
Phenotype-Guided Decision Tree
Methodology + Pattern discipline
Cross-cutting clinical considerations
Module 5 lesson cross-reference
Source citations + further reading
Version + update history

Cross-references — methodology and infrastructure

Protocol template: [[Protocol Template]] — the 12-section + 3-appendix structural authority every per-canonical and adjunct protocol mirrors
Editorial framework: [[Synergy Editorial Framework]] v1.2 — voice, framing discipline, length expectations, citation authority, Pattern AA.marketing-claims convention, Pattern Z.injection-framing, Pattern Z.research-precision
System observations: [[AC2-26 – System Observations]] — the full Pattern catalog (R / R.1 / R.2 / V / W / Z + sub-patterns / AA + sub-patterns / AB.1 / AB.2 / AB.4 / N.1)
Voice profile: [[Voice Profile – Dr. Jeff Gross MD]] — clinician-voice calibration
Pattern Z calibration anchor: /Internal/Module-5-Pipeline/pattern-z-calibration-anchor.md — the five verbatim-correct counseling-beat anchors (compounded formulations; pregnancy framing; comparator framing; investigational compounds; off-label adjuncts) that every Module 5 protocol’s §10 mirrors

§1 Welcome + how to use this protocol library

1.1 What Module 5 covers

Module 5 of the Pepteon Academy curriculum and clinician-reference library covers weight loss, body composition, and metabolic disease peptide therapeutics — the compound class that, between 2017 and 2026, transitioned from a single-indication adjunct-to-lifestyle pharmacotherapy (liraglutide 3.0 mg in 2014; semaglutide 1.0 mg for T2D in 2017) into the dominant pharmacologic platform for chronic weight management, type 2 diabetes mellitus, cardiovascular risk reduction in established disease, metabolic dysfunction-associated steatohepatitis (MASH), chronic kidney disease (CKD) in T2D, obstructive sleep apnea (OSA) with obesity, and — under active Phase 3 evaluation — heart failure with preserved ejection fraction (HFpEF) related to obesity, Alzheimer disease, alcohol use disorder, and several additional indications.

The Module 5 portfolio is anchored by the GLP-1 receptor agonist (GLP-1 RA) class — liraglutide, semaglutide, and orforglipron (small-molecule non-peptide oral GLP-1R agonist) — extended by dual coagonists (tirzepatide at GIP + GLP-1 receptors; survodutide at glucagon + GLP-1 receptors), triple coagonists (retatrutide at GIP + GLP-1 + glucagon receptors), amylin analogs (cagrilintide), combination products (CagriSema = cagrilintide + semaglutide; IcoSema = once-weekly insulin icodec + semaglutide), and adjunct peptide therapeutics for visceral-fat-specific targeting (tesamorelin; AOD-9604), lean-mass preservation during caloric-deficit weight loss (CJC-1295 + ipamorelin GHRH-axis stacks; MOTS-c mitochondrial-derived peptide), and post-weight-loss skin laxity (GHK-Cu copper tripeptide).

The protocol library covers nine canonical compounds (the dominant clinical actors), three adjunct protocol families (the targeted-effect compounds clinicians layer onto canonical therapy), and one phenotype-guided decision tree (the compound-selection algorithm that operationalizes the choice across the nine canonicals plus adjuncts). The library is built against a unified structural template ([[Protocol Template]]) and a unified Pattern discipline (the AC2-26 Pattern catalog) — every protocol is structurally homologous, every regulatory-state claim is Pattern AA-precise, every counseling beat passes Pattern Z verbatim-anchor calibration.

1.2 The 9 + 3 + 1 protocol library structure

The Module 5 protocol library at /obsidian-peptides/Protocols/ contains thirteen protocol documents organized in three tiers plus this index:

Tier 1 — Nine per-canonical protocols. One protocol per canonical compound, each structured per the [[Protocol Template]] (12 sections + 3 appendices), each backed by a v1.0-final canonical reference document at /obsidian-peptides/Peptides/[Compound].md, each carrying full Pattern discipline (R / R.1 / R.2 / V / W / Z including verbatim-anchor compliance at §10 / AA / AB.1 / AB.2 / AB.4):

[[Semaglutide Protocol]] — Wave 1 lead exemplar (the calibration baseline subsequent canonicals mirror)
[[Tirzepatide Protocol]] — Wave 1
[[Retatrutide Protocol]] — Wave 1
[[Cagrilintide Protocol]] — Wave 2
[[CagriSema Protocol]] — Wave 2
[[IcoSema Protocol]] — Wave 2
[[Survodutide Protocol]] — Wave 2
[[Liraglutide Protocol]] — Wave 3 #1
[[Orforglipron Protocol]] — Wave 3 #2

Tier 2 — Three adjunct protocols. One protocol per adjunct therapeutic family, each structured per the same Protocol Template (adapted to phenotype-narrower scope per Editorial Framework §1.6), each backed by canonical references at /obsidian-peptides/Peptides/, each carrying the same Pattern discipline. Adjuncts are compounds clinicians layer onto canonical GLP-1 RA / coagonist / amylin therapy to address a specific phenotype-narrow problem the canonical does not address:

[[Tesamorelin + AOD-9604 – Visceral Fat Adjunct Protocol]] — visceral-adipose-tissue (VAT) reduction in the lipodystrophy phenotype and the metabolic-dysfunction-associated steatotic liver disease (MASLD / MASH-pre-fibrotic) phenotype where canonical GLP-1 RA produces subcutaneous-dominant fat-mass reduction but VAT-specific reduction may be the indication-defining outcome
[[CJC-1295 + Ipamorelin + MOTS-c – Lean Mass Preservation Stack Protocol]] — lean-mass preservation during caloric-deficit weight loss in phenotypes where lean-mass loss is a concern (older adults ≥65; high baseline lean mass; athletic populations; sarcopenic-obesity phenotype)
[[GHK-Cu – Post-Weight-Loss Skin Laxity Protocol]] — post-weight-loss skin laxity in patients who have achieved substantial weight loss on canonical therapy and present with cosmetic / functional skin-laxity complaint

Tier 3 — One phenotype-guided decision-tree protocol. The operational compound-selection algorithm that walks a clinician from patient phenotype to recommended canonical (plus adjunct if applicable) using the M5.1 phenotype taxonomy and the canonical-comparator landscape:

[[Module 5 – Phenotype-Guided Decision Tree Protocol]] — Wave 3 #3 (the structural bridge between the nine canonicals + three adjuncts and the individual patient encounter)

Tier 0 — This index. The top-level wayfinder.

1.3 Recommended reading order for clinicians new to the library

The protocol library is large (~17,000 cumulative protocol words across the 13 documents, plus appendices). A clinician new to Module 5 protocols does not need to read every protocol cover-to-cover before initiating therapy in a patient. The recommended reading order is calibrated to a clinician who is comfortable prescribing GLP-1 RAs (semaglutide and/or tirzepatide) in routine practice and is now adopting the full Module 5 protocol library as their reference framework:

Step 1 — Read this index in full (30 minutes). End state: you know what every protocol is for, when to reach for which one, where the methodology lives, and what the Pattern discipline means for how you read each protocol.

Step 2 — Read the [[Semaglutide Protocol]] as the structural exemplar (60–90 minutes). Semaglutide was the Wave 1 lead canonical. Its protocol is the most fully populated (six FDA-approved-for-marketing-claims indications; the longest §10 patient-counseling-beats section in the library) and is the structural model every subsequent protocol mirrors. Reading semaglutide first gives you the template’s full shape — once you see how Section 1 (indication scope) builds into Section 4 (initiation), Section 6 (AE management), Section 9 (combination rules), and Section 10 (counseling beats), every other protocol becomes navigable.

Step 3 — Read the [[Tirzepatide Protocol]] as the dual-receptor-coagonist exemplar (60 minutes). Tirzepatide introduces the dual GIP/GLP-1 receptor pharmacology that frames how dual coagonists differ structurally from single-receptor GLP-1 RAs. The NAION class-differentiation finding (Lawrenson 2025; signal-present for semaglutide, signal-absent for tirzepatide at the same pharmacovigilance threshold), the head-to-head SURMOUNT-5 weight-loss-magnitude data, and the OSA-with-obesity indication (December 2024 FDA approval based on SURMOUNT-OSA) are all introduced here.

Step 4 — Read the [[Module 5 – Phenotype-Guided Decision Tree Protocol]] (45 minutes). With semaglutide and tirzepatide as structural anchors, the decision tree operationalizes the choice between them and across the broader portfolio. The decision tree is the workhorse document for everyday encounter use — it is the document you will return to most often.

Step 5 — Read the remaining seven per-canonical protocols selectively, indication-driven (variable time). Once the structural template is internalized, the remaining canonicals are read on a need-to-know basis. A clinician treating a patient with a specific phenotype — pediatric obesity (Wegovy adolescent indication), T2D + CKD (FLOW-based semaglutide indication; Zepbound CKD pipeline), MASH F2-F3 (ESSENCE-based semaglutide indication; SYNERGY-NASH-pending tirzepatide), HFpEF + obesity (STEP-HFpEF; SUMMIT for tirzepatide), pre-FDA-approval-for-marketing-claims compound consideration (retatrutide TRIUMPH program; survodutide SYNCHRONIZE program) — reaches for the specific protocol indication-driven. The Pattern discipline ensures protocols read consistently; you do not need to re-learn the template per molecule.

Step 6 — Read the three adjunct protocols when a phenotype-narrow indication arises in your practice (30–45 minutes each). Visceral-fat-dominant phenotype not adequately addressed by canonical → [[Tesamorelin + AOD-9604 – Visceral Fat Adjunct Protocol]]. Lean-mass-loss concern during canonical weight loss → [[CJC-1295 + Ipamorelin + MOTS-c – Lean Mass Preservation Stack Protocol]]. Post-weight-loss skin laxity → [[GHK-Cu – Post-Weight-Loss Skin Laxity Protocol]]. Adjuncts are not first-line therapy and are not used in every patient on canonical therapy; the protocols specify which phenotype-narrow indications they target.

Step 7 — Methodology and Pattern discipline as a deep-read on a quiet afternoon (90 minutes). [[Synergy Editorial Framework]] v1.2 (§1.2.1, §1.4, §1.6) plus [[AC2-26 – System Observations]] (Patterns R, R.1, R.2, V, W, Z and its sub-patterns, AA and its sub-patterns, AB.1, AB.2, AB.4, N.1). This step is optional for clinical use of the protocols; it is recommended for clinicians who want to read the protocols against the methodological frame that produced them, and required for clinicians who plan to contribute back to the library.

1.4 How protocols relate to Module 5 lessons and to canonical reference documents

The Module 5 content corpus has three layers, organized by depth and audience:

Layer 1 — Module 5 lessons (clinical-education layer; M5.1 through M5.10 at /Peptide Projects/Pepteon Academy/m5-content/). The lessons are the clinician-education layer: they teach the pathophysiology (M5.1), the dominant mechanisms and trial-program magnitudes (M5.2 GLP-1 RAs / semaglutide; M5.3 dual coagonists / tirzepatide; M5.4 liraglutide and emerging pipeline; M5.5 tesamorelin + AOD-9604; M5.6 lean-mass preservation; M5.7 GHK-Cu skin laxity), the titration and AE management algorithms (M5.8), the lab-panel framework (M5.9), and the integrated case study (M5.10). The lessons are how a clinician new to peptide therapeutics builds the framework. The lessons are written for learning; they include knowledge-check questions, clinical-application scenarios, and FAQ patient-counseling exemplars. Cumulative lesson length: ~28,000 words across 10 lessons + quiz + sources. The lesson-to-protocol cross-reference table is in §8 of this index.

Layer 2 — Per-compound protocols (clinician-reference layer; the 13 protocols in this library at /obsidian-peptides/Protocols/). The protocols are the clinician-reference layer: they translate the lesson-level pathophysiology and trial-program magnitudes into operational clinical decisions — who to start (Section 1, 2), what pre-treatment workup (Section 3), what initiation dose and titration cadence (Section 4), what maintenance and dose adjustment (Section 5), what AE management algorithm by AE class (Section 6), what plateau and non-response algorithm (Section 7), what discontinuation and tapering decisions (Section 8), what combination rules (Section 9), what patient-counseling beats with Pattern Z verbatim-anchor calibration (Section 10), what source citations (Section 11), and what clinical decision tree applies (Section 12). Cumulative protocol length: ~17,000 words across the 9 canonicals + 3 adjuncts + 1 decision-tree, plus this index.

Layer 3 — Canonical reference documents (deep-evidence layer at /obsidian-peptides/Peptides/[Compound].md). The canonicals are the deep-evidence layer: they document the full evidence base behind each compound — mechanism with primary-source citation, pharmacokinetics, pharmacodynamics, every trial in the program (Phase 1 through Phase 3 plus pivotal post-approval extensions) with NCT identifiers and PMIDs and effect-size anchors, the bibliography of verified PMIDs, the iteration log of how the canonical was constructed and verified. Canonicals are the documents to consult when a clinical question demands evidence-grade detail beyond the protocol’s operational summary — when a patient asks a specific trial-design question, when a journal-club discussion requires primary-source triangulation, when a Pattern AA / Pattern V / Pattern AB.4 audit requires source verification. The semaglutide canonical at /obsidian-peptides/Peptides/Semaglutide.md is the calibration baseline (~1,930 verified PMIDs; v1.0-final 2026-05-08).

The three layers are designed to interlock. A clinician’s workflow:

Encountering a phenotype-novel patient → start at the decision tree protocol (Tier 3) for compound selection
Selecting a compound → consult the relevant per-canonical protocol (Tier 1) for operational specifics
Encountering a specific evidence-detail question (trial design, secondary endpoint, sub-population data, mechanism precision) → consult the relevant canonical (Layer 3)
Encountering a teaching moment (resident, fellow, patient-education conversation, journal club) → consult the relevant Module 5 lesson (Layer 1)

This index is the wayfinder across all three layers.

1.5 What to expect from each per-compound protocol (the structural template at a glance)

Every per-compound protocol — canonical or adjunct — is structured per [[Protocol Template]] v1.0 with the following twelve sections plus three appendices:

Section	What it answers
§1 Indication scope + phenotypes	Where does this molecule apply? Which patient phenotypes does it target? What is the regulatory state per indication (FDA-approved for marketing claims; off-label with primary-source support; investigational pending Phase 3)?
§2 Selection criteria	Who is the molecule for (inclusion)? Who requires clinician judgment (relative exclusion)? Who must not receive it (hard contraindication)?
§3 Pre-treatment workup	What labs, imaging, and clinical assessment must be completed before initiation?
§4 Initiation protocol	What is the starting dose, the titration cadence, the first-month monitoring posture?
§5 Maintenance protocol	What is the maintenance dose, the dose-adjustment criteria, the long-term monitoring cadence?
§6 Side-effect management	By AE class (GI / hepatobiliary / pancreatic / renal / endocrine / dermatologic / ophthalmologic / cardiovascular / psychiatric / musculoskeletal), what is the recognition, evaluation, and management algorithm?
§7 Plateau + non-response algorithm	If the patient plateaus or fails to respond, what is the diagnostic and therapeutic algorithm?
§8 Discontinuation + tapering	When and how is the molecule discontinued (pregnancy planning; AE-driven; goal-met; intolerance; transition to another agent)?
§9 Combination rules	What molecules combine with this one? What molecules must not be combined? What is the evidence state for each combination?
§10 Patient counseling beats	What patient-facing fact-based scripts (Pattern Z verbatim-anchor-calibrated) does the clinician deliver for the recurring patient-question categories?
§11 Source citations	What are the primary sources for every load-bearing claim in §1 through §10?
§12 Clinical decision tree	At a glance, what is the operational compound-and-phenotype decision algorithm for this molecule?

Appendices: A. Verification gate (the four-step pre-publication cycle every protocol passes); B. Pattern discipline self-audit; C. Byte-count audit and commit log.

The structural homology across protocols means that once you read one fully (recommendation: start with [[Semaglutide Protocol]]), every other protocol becomes navigable by section number. You do not need to re-orient per molecule.

1.6 Pattern discipline in 60 seconds (the longer treatment is in §6)

Every protocol in this library is built against the AC2-26 Pattern catalog (see [[AC2-26 – System Observations]]). The five Pattern families load-bearing across Module 5:

Pattern R / R.1 / R.2 — anti-deficit-leading framing. Lead with what the molecule does and for whom, not with what it excludes or what regulatory limits constrain it. Indication scope is locked at design-time, not drifted mid-draft.
Pattern V — direction-of-effect verification. Every claim about effect direction (positive endpoint, negative endpoint, neutral signal) traces to a specific trial sub-population and is not over-generalized.
Pattern W — cross-section consistency. The same fact framed identically across the protocol (mechanism in §1, AE class in §6, counseling beat in §10 all anchor to the same primary source).
Pattern Z — steering-direction test. “The canonical presents facts. It does not steer clinical decisions.” §10 of every protocol passes verbatim-anchor calibration against the five anchors at /Internal/Module-5-Pipeline/pattern-z-calibration-anchor.md. Sub-patterns: Z.injection-framing (self-injection is a routine clinical skill, not a daunting barrier — Dr. Gross 2026-05-13 calibration); Z.research-precision (bias-vocabulary like “highly experimental” / “fringe” / “unproven” is a Pattern Z violation; replace with research-state precision).
Pattern AA / AA.marketing-claims — regulatory-state precision. “FDA-approved for marketing claims for [indication X]” is the load-bearing phrasing; “FDA-approved” without indication-anchoring imports drug-level claims that are indication-level facts.

Pattern N.1 governs the small-molecule-vs-peptide path: tirzepatide is a peptide (39-amino-acid synthetic; SC injection); orforglipron is a small molecule (non-peptide oral GLP-1R agonist); their protocols live at distinct file-system paths reflecting class. Patterns AB.1 / AB.2 / AB.4 enforce identifier-integrity standing scans (NCT-to-trial-to-PMID triangulation; sponsor-to-trial linkage; publication-type accuracy).

The longer treatment of each pattern with worked examples is in §6 of this index.

§2 Module 5 compound portfolio at a glance

2.1 Portfolio overview table

The Module 5 protocol library covers nine canonical compounds plus three adjunct compound families. The table below summarizes class, mechanism, FDA regulatory state (Pattern AA.marketing-claims precision), the indication-pivotal trial program, and the protocol link. Pre-FDA-approval-for-marketing-claims compounds are framed per Pattern Z.research-precision in their Regulatory state column.

#	Compound (canonical)	Class	Mechanism	FDA regulatory state (Pattern AA.marketing-claims precision)	Indication-pivotal trial program	Protocol
1	Semaglutide (Ozempic / Wegovy / Wegovy HD 7.2 mg / oral Wegovy 25 mg / Rybelsus)	GLP-1 RA (peptide; SC injection + oral)	Single-receptor GLP-1 agonist with 7-day half-life; SC weekly or oral daily	FDA-approved for marketing claims: T2D (Ozempic 2017; Rybelsus oral 2019); chronic weight management (Wegovy 2.4 mg 2021; Wegovy HD 7.2 mg via Commissioner’s National Priority Voucher Program, March 19, 2026; oral Wegovy 25 mg via OASIS program, August 2025; adolescent CWM ≥12 years via STEP-TEENS, 2022); CV risk reduction in established CVD with T2D (Ozempic, 2020; SUSTAIN-6-based) and in ASCVD with BMI ≥27 without diabetes (Wegovy, SELECT-based label expansion 2024); MASH F2–F3 (Wegovy, ESSENCE-based label expansion August 2025); CKD in T2D (Ozempic, FLOW-based label expansion 2025)	SUSTAIN (T2D) / PIONEER (oral T2D) / STEP including STEP-TEENS adolescent and STEP-HFpEF / STEP UP (Wegovy HD) / OASIS (oral Wegovy) (CWM) / SELECT (CV) / ESSENCE (MASH) / FLOW (CKD) / SOUL (oral semaglutide CV)	[[Semaglutide Protocol]]
2	Tirzepatide (Mounjaro / Zepbound)	Dual coagonist GIP + GLP-1 RA (peptide; SC injection)	Dual receptor agonism with biased affinity (Coskun 2018 PMID 30473097: GIPR at native-GIP-like affinity; GLP-1R at ~5-fold lower affinity than native GLP-1); 5-day half-life; SC weekly	FDA-approved for marketing claims: T2D (Mounjaro 2022); chronic weight management (Zepbound 2023); moderate-to-severe OSA with obesity (Zepbound December 2024). MASH program (SYNERGY-NASH Phase 2 PMID 38856224; Phase 3 in development), HFpEF + obesity (SUMMIT PMID 39555826), and CV outcomes (SURMOUNT-MMO NCT05556512 Phase 3 ACTIVE_NOT_RECRUITING, primary completion 2027-10) are pre-approval.	SURPASS (T2D) / SURMOUNT including SURMOUNT-1 through SURMOUNT-5 head-to-head vs semaglutide and SURMOUNT-OSA (CWM + OSA) / SURMOUNT-MMO (CV, in development) / SUMMIT (HFpEF) / SYNERGY-NASH (MASH, in development)	[[Tirzepatide Protocol]]
3	Retatrutide	Triple coagonist GIP + GLP-1 + glucagon (peptide; SC injection)	Triple receptor agonism; glucagon-axis activation hypothesized to drive incremental energy-expenditure contribution beyond GIP/GLP-1; SC weekly	Pre-FDA-approval-for-marketing-claims. TRIUMPH program reading out across multiple indications (TRIUMPH-1 obesity Phase 2 PMID 37354645 reported ~24% body-weight loss at 12 mg/48 weeks; TRIUMPH-4 sponsor topline December 2025 reported ~28.7% body-weight loss at 12 mg). Phase 3 readout pending.	TRIUMPH (TRIUMPH-1 Phase 2 obesity; TRIUMPH-2 T2D; TRIUMPH-3 obesity with CV risk; TRIUMPH-4 obesity Phase 3)	[[Retatrutide Protocol]]
4	Survodutide (BI 456906)	Dual coagonist glucagon + GLP-1 RA (peptide; SC injection)	Glucagon-receptor + GLP-1R coagonism; glucagon-axis activation distinguishes from tirzepatide’s GIP-axis activation; SC weekly	Pre-FDA-approval-for-marketing-claims. SYNCHRONIZE program reading out across obesity and MASH; Boehringer Ingelheim / Zealand Pharma co-development. SYNCHRONIZE-1 / -2 obesity Phase 3, SYNCHRONIZE-NASH MASH Phase 3 (NCT06632327). Phase 2 obesity (Le Roux 2024 PMID 38446694) reported ~19% body-weight loss at 4.8 mg/46 weeks.	SYNCHRONIZE (obesity); SYNCHRONIZE-NASH (MASH)	[[Survodutide Protocol]]
5	Liraglutide (Victoza / Saxenda / Xultophy 100/3.6)	GLP-1 RA (peptide; SC injection, daily)	Single-receptor GLP-1 agonism with 13-hour half-life; SC daily	FDA-approved for marketing claims: T2D in adults (Victoza, January 25, 2010); CV risk reduction in T2D + established CVD (Victoza label expansion, August 25, 2017; LEADER-based); pediatric T2D ≥10 years (Victoza label expansion, June 17, 2019; ELLIPSE-based); chronic weight management in adults (Saxenda, December 23, 2014); chronic weight management in adolescents ≥12 years with body weight >60 kg and BMI ≥95th percentile age-and-sex-adjusted (Saxenda label expansion, December 4, 2020; SCALE-Teens-based); insulin degludec + liraglutide fixed-ratio combination for T2D (Xultophy 100/3.6, November 21, 2016; DUAL program). Multiple FDA-approved generic ANDAs 2024–2025 (off-patent transition).	LEAD (T2D) / SCALE-Obesity-and-Prediabetes / SCALE-Maintenance / SCALE-Diabetes / SCALE-Sleep-Apnea (CWM) / LEADER (CV) / ELLIPSE (pediatric T2D) / SCALE-Teens (pediatric obesity) / DUAL (Xultophy combination)	[[Liraglutide Protocol]]
6	Cagrilintide	Amylin analog (long-acting peptide; SC injection)	Long-acting amylin receptor agonism; reduces postprandial glucose excursion and slows gastric emptying via distinct mechanism from GLP-1 RAs; SC weekly. Lacefield 2024 / Frias 2023 (Phase 2) characterized monotherapy weight loss; the registration-evaluated combination is CagriSema.	Pre-FDA-approval-for-marketing-claims as monotherapy. Phase 2 monotherapy data (Lacefield 2024; Frias 2023) reported ~10% body-weight loss at 4.5 mg/26 weeks. Co-development pathway is via the CagriSema combination product (REDEFINE Phase 3 program).	Phase 2 monotherapy program; REDEFINE Phase 3 (combination CagriSema)	[[Cagrilintide Protocol]]
7	CagriSema	Combination amylin analog + GLP-1 RA (cagrilintide + semaglutide; peptide; SC injection)	Combination amylin + GLP-1 receptor agonism; dual-mechanism appetite reduction with complementary GI-tolerability profile (cagrilintide attenuates GLP-1-RA-mediated GI AE in early titration); SC weekly	Pre-FDA-approval-for-marketing-claims. REDEFINE Phase 3 program (REDEFINE-1 obesity; REDEFINE-2 obesity with T2D; REDEFINE-3 obesity with established CVD) reading out 2025–2026. REDEFINE-1 obesity reported ~22.7% body-weight loss at 68 weeks (sponsor topline 2025). REDEFINE-2 obesity-with-T2D reported ~13.7% body-weight loss (sponsor topline 2025) — the smaller magnitude in the T2D phenotype mirrors the STEP-1-vs-STEP-2 magnitude pattern for semaglutide.	REDEFINE (REDEFINE-1, -2, -3)	[[CagriSema Protocol]]
8	IcoSema (EU brand: Kyinsu)	Combination once-weekly insulin icodec + semaglutide (peptide; SC injection)	Combination ultra-long-acting basal insulin (icodec; ~1-week half-life) + GLP-1 RA (semaglutide); single weekly subcutaneous injection for T2D requiring basal-insulin intensification; SC weekly	EMA-approved-for-marketing-claims as Kyinsu (EC marketing authorization decision 24 November 2025) for T2D in adults whose condition remains inadequately controlled on either basal insulin OR a GLP-1 receptor agonist, used alongside diet, exercise, and oral antidiabetic medications. Pre-FDA-approval-for-marketing-claims in the US as of 2026-05-13; FDA submission status not publicly disclosed. Component-level: insulin icodec FDA-approved as Awiqli (2024-04-23) for T2D; semaglutide FDA-approved across multiple indications. COMBINE Phase 3 program (COMBINE-1, COMBINE-2, COMBINE-3) anchored the registration; COMBINE-1 vs basal-bolus icodec demonstrated non-inferior HbA1c reduction with lower body weight and lower hypoglycemia.	COMBINE (COMBINE-1, -2, -3)	[[IcoSema Protocol]]
9	Orforglipron	Small-molecule non-peptide oral GLP-1R agonist (oral once-daily)	Non-peptide GLP-1R agonist; oral bioavailability without absorption-enhancer requirement (distinguishes from oral semaglutide / Rybelsus, which uses SNAC absorption enhancer and requires fasting administration); oral daily	Pre-FDA-approval-for-marketing-claims. ACHIEVE program (T2D) and ATTAIN program (obesity) Phase 3 readouts 2025–2026. ACHIEVE-1 T2D sponsor topline 2025 reported HbA1c reduction ~1.3–1.6 percentage points at 36 mg. ATTAIN-1 obesity sponsor topline 2025 reported ~11% body-weight loss at 36 mg/72 weeks. Eli Lilly NDA submission process. Pattern N.1 enforcement: oral non-peptide small-molecule path, distinct from oral peptide path (Rybelsus).	ACHIEVE (T2D); ATTAIN (CWM)	[[Orforglipron Protocol]]

Adjunct compound families (Tier 2):

Adjunct family	Compounds	Class	Phenotype-narrow indication	Regulatory state (Pattern AA.marketing-claims precision)	Protocol
Visceral fat / VAT-specific	Tesamorelin + AOD-9604	Tesamorelin: GHRH analog (peptide; SC daily). AOD-9604: synthetic C-terminal fragment of human growth hormone (peptide; off-label / cosmetic-grade)	Visceral-fat-dominant phenotype where canonical GLP-1 RA produces subcutaneous-dominant loss; MASLD/MASH-pre-fibrotic phenotype with VAT-driven hepatic-steatosis component; HIV-associated lipodystrophy (the FDA-approved-for-marketing-claims indication for tesamorelin)	Tesamorelin: FDA-approved for marketing claims for HIV-associated lipodystrophy (Egrifta 2010); off-label for non-HIV visceral adiposity and MASLD with primary-source support (Stanley JAMA 2014 PMID 25038357; Tesamorelin Body Composition Meta-Analysis PMID 41545261). AOD-9604: not FDA-approved for marketing claims for any drug indication; pre-clinical and early-human development for obesity terminated; available through 503A compounding pharmacy pathways for off-label use; cosmetic-grade topical formulations exist.	[[Tesamorelin + AOD-9604 – Visceral Fat Adjunct Protocol]]
Lean mass preservation	CJC-1295 (no-DAC and with-DAC variants) + Ipamorelin + MOTS-c	CJC-1295: GHRH analog (peptide; SC). Ipamorelin: GHRP / ghrelin-mimetic (peptide; SC). MOTS-c: 16-amino-acid mitochondrial-derived peptide (peptide; SC)	Lean-mass-loss concern during canonical caloric-deficit weight loss; older adult ≥65 with sarcopenic-obesity phenotype; high-baseline-lean-mass / athletic populations; post-bariatric or post-GLP-1-RA rapid-weight-loss with DEXA-documented lean-mass reduction	CJC-1295 / Ipamorelin: not FDA-approved for marketing claims for any drug indication; available through 503A compounding pharmacy pathways for off-label use. WADA-prohibited for competitive athletes (S2.2 peptide hormones). MOTS-c: investigational; the current evidence base is Lee 2015 Cell Metab mechanism characterization (PMID 25738459) + animal studies (PMID 36677050; PMID 33473109) + early human pharmacology; no Phase 3 trials have been completed for any indication.	[[CJC-1295 + Ipamorelin + MOTS-c – Lean Mass Preservation Stack Protocol]]
Post-weight-loss skin laxity	GHK-Cu	Copper tripeptide-1 (glycyl-L-histidyl-L-lysine + Cu²⁺); peptide; topical / SC / intradermal	Post-weight-loss skin laxity in patients who have achieved substantial weight loss on canonical therapy and present with cosmetic / functional skin-laxity complaint; chronologic skin aging (the cosmetic-industry-anchored use case)	Not FDA-approved for marketing claims for any drug indication; topical cosmetic formulations are widely marketed under cosmetic-ingredient classification; injectable preparations are available through 503A compounding pharmacy pathways for off-label use. RCT-level human evidence for the post-weight-loss-laxity-specific indication is research-state-incomplete; supporting evidence base is in vitro fibroblast collagen-synthesis data (Maquart 1988, 1993), animal wound-healing models, cosmetic-industry topical efficacy data, and practitioner clinical experience.	[[GHK-Cu – Post-Weight-Loss Skin Laxity Protocol]]

Tier 3 — phenotype-guided decision tree:

Protocol	What it does
[[Module 5 – Phenotype-Guided Decision Tree Protocol]]	Operationalizes compound selection across the nine canonicals plus three adjunct families using the M5.1 phenotype taxonomy (metabolic phenotype; adiposity distribution; appetite phenotype; energy-expenditure phenotype; comorbidity load; pharmacologic history; life-stage modifier). Walks the clinician from patient presentation → canonical first-line selection → adjunct layering decision → AE-driven and plateau-driven branch decisions. The decision tree is the workhorse compound-selection document for everyday encounter use.

Protocol

What it does

[[Module 5 – Phenotype-Guided Decision Tree Protocol]]

Operationalizes compound selection across the nine canonicals plus three adjunct families using the M5.1 phenotype taxonomy (metabolic phenotype; adiposity distribution; appetite phenotype; energy-expenditure phenotype; comorbidity load; pharmacologic history; life-stage modifier). Walks the clinician from patient presentation → canonical first-line selection → adjunct layering decision → AE-driven and plateau-driven branch decisions. The decision tree is the workhorse compound-selection document for everyday encounter use.

2.2 Portfolio coverage commentary

The Module 5 portfolio, as of 2026-05-13, covers the full operative space of the GLP-1-receptor pharmacology era of metabolic therapeutics. Five class-level observations frame how the portfolio reads:

(a) GLP-1 receptor agonists — three molecules, three platforms. Liraglutide (daily SC; 13-hour half-life; class-foundational; pediatric-indication-extended), semaglutide (weekly SC + oral; 7-day half-life; the broadest indication scope of any GLP-1 RA), and orforglipron (oral daily small-molecule; non-peptide; the first oral platform that does not require an absorption enhancer). The three molecules span the full GLP-1-RA pharmacologic envelope from daily injectable to weekly injectable to oral small molecule. Pattern N.1 enforcement: orforglipron is structurally a small molecule, not a peptide, despite acting at the GLP-1 receptor; its file-system path is /obsidian-peptides/Protocols/Orforglipron Protocol.md but its compound-class framing throughout is non-peptide-small-molecule.

(b) Dual coagonists — GIP + GLP-1, and glucagon + GLP-1. Tirzepatide (GIP + GLP-1; the dominant dual coagonist by approval state and exposure) and survodutide (glucagon + GLP-1; pre-approval; the SYNCHRONIZE program). These two molecules represent the two distinct dual-coagonist mechanism families — GIP-axis activation (tirzepatide) versus glucagon-axis activation (survodutide). The protocols frame the mechanism precision throughout: tirzepatide is not described as “stronger GLP-1 RA” but as dual GIP/GLP-1; survodutide is not described as “another tirzepatide” but as glucagon + GLP-1.

(c) Triple coagonist — retatrutide. GIP + GLP-1 + glucagon. Pre-approval (TRIUMPH program). The triple-coagonist mechanism layers glucagon-axis energy-expenditure-incremental contribution onto the dual-GIP/GLP-1 receptor stack. The Phase 2 TRIUMPH-1 readout (PMID 37354645; ~24% body weight loss at 12 mg / 48 weeks) and TRIUMPH-4 sponsor topline (~28.7% at 12 mg) are the dominant magnitudes-of-effect anchors in the portfolio’s upper-bound. Pattern AA precision: retatrutide is pre-FDA-approval-for-marketing-claims; framing throughout is “investigational; TRIUMPH program reading out” not “approved-pending” or “next-generation FDA drug.”

(d) Amylin axis and combination products — cagrilintide, CagriSema, IcoSema. Cagrilintide is the long-acting amylin analog used as monotherapy in Phase 2 (~10% body-weight loss at 4.5 mg / 26 weeks) and as the amylin partner in the registration-evaluated CagriSema combination (REDEFINE Phase 3). IcoSema is the once-weekly insulin icodec + semaglutide combination (COMBINE Phase 3) for T2D requiring basal-insulin intensification. These three protocols (Cagrilintide / CagriSema / IcoSema) together cover the amylin-class therapeutic space and the basal-insulin-GLP-1-RA combination space.

(e) Oral non-peptide path — orforglipron. Orforglipron is the first non-peptide small-molecule GLP-1R agonist with Phase 3 data in obesity (ATTAIN program) and T2D (ACHIEVE program). The oral once-daily small-molecule platform differentiates from oral peptide platforms (Rybelsus / oral Wegovy 25 mg with SNAC absorption enhancer) on absorption mechanism, food/PPI interactions, and synthetic chemistry (chemical synthesis vs solid-phase peptide synthesis at scale). Pattern N.1 governs the small-molecule path; the orforglipron protocol carries the full N.1 enforcement at file-system placement, compound-class framing, and mechanism-precision-driven section architecture.

Adjunct portfolio — three families, three phenotype-narrow indications. Tesamorelin + AOD-9604 (visceral-fat-specific; the indication where canonical GLP-1 RA may produce subcutaneous-dominant loss and the patient’s clinical priority is VAT-specific reduction). CJC-1295 + Ipamorelin + MOTS-c (lean-mass-preservation during caloric-deficit weight loss; the indication where canonical-driven rapid weight loss exceeds physiologic lean-mass-loss tolerance). GHK-Cu (post-weight-loss skin laxity; the cosmetic / functional indication that arises after substantial weight loss has been achieved). The adjuncts are not first-line therapy; they are phenotype-narrow layers onto canonical therapy.

Phenotype-guided decision tree — the integration layer. The decision-tree protocol is what binds the nine canonicals and three adjunct families to the individual patient encounter. It is the document that operationalizes the choice — for this patient with this phenotype, in this clinical context, the recommended starting compound is X; the recommended adjunct (if any) is Y; the decision branch points are at A, B, C.

2.3 What this portfolio does not cover

Pattern R.1 enforcement at this section: lead with what is covered, not what is excluded. Coverage scope above. Brief scope-anchoring for what falls outside Module 5 protocol scope:

Bariatric surgery is referenced in protocols as a comparator and as a context for post-bariatric weight regain (a phenotype where canonical GLP-1 RA / coagonist therapy is increasingly used). Bariatric-surgery-as-primary-intervention is outside Module 5 protocol scope; Synergy clinical-education content addresses it at the integration layer (M5.10 case study; decision-tree protocol §branch points).
Non-pharmacologic weight-loss interventions (caloric-deficit diet, structured-exercise prescription, behavioral therapy, sleep-and-stress-mediator optimization) are framed throughout the protocols as adjunct-to-pharmacologic rather than substitute-for-pharmacologic. Every per-canonical protocol’s §1 indication scope and §10 patient-counseling beats anchor the molecule’s role within a comprehensive treatment frame including nutrition, activity, and behavioral support.
Older-generation weight-loss pharmacotherapy (phentermine; phentermine/topiramate; naltrexone-bupropion; orlistat) is referenced in protocols as comparator (Section 9 combination rules; Section 10 historical-context counseling beats) but is not the primary protocol scope. The Module 5 protocol library is anchored at the GLP-1-receptor pharmacology era.
Investigational compounds beyond the nine canonicals (e.g., maritide, mazdutide, eloralintide, ecnoglutide, several MK-series Merck compounds) are mentioned in canonicals’ competitive-landscape sections where relevant; protocol-level coverage requires Phase 3 readout state and is updated at protocol-revision cadence.

§3 Per-canonical protocols (the nine)

Section §3 summarizes each of the nine per-canonical protocols in approximately one paragraph per protocol: what the compound is, what indication scope the protocol covers, when to reach for the protocol versus alternatives, and a link into the full protocol document. The summaries are wayfinders — they do not duplicate the operational specifics, which live in §1 through §12 of each protocol.

The nine canonicals are presented in roughly chronological order of FDA-approval-for-marketing-claims state (semaglutide first as the Wave 1 lead exemplar; the pre-approval compounds — retatrutide, survodutide, cagrilintide, CagriSema, IcoSema, orforglipron — last). This order also approximates the order of complexity of the protocol document: the semaglutide protocol is the longest and structurally most fully populated; the pre-approval-compound protocols are calibrated tighter per Editorial Framework §1.6 (length is a function of evidence density, not a target).

3.1 Semaglutide — [[Semaglutide Protocol]]

Compound. Semaglutide is a 31-amino-acid GLP-1 receptor agonist developed by Novo Nordisk, marketed as Ozempic (injectable T2D), Wegovy (injectable chronic weight management), Wegovy 7.2 mg HD (high-dose injectable CWM), and Rybelsus (oral T2D). Half-life ~7 days enables once-weekly SC injection (Ozempic / Wegovy / Wegovy HD) or once-daily oral administration (Rybelsus, formulated with SNAC absorption enhancer requiring 30-minute pre-meal fasting administration). The injectable platform is a routine clinical skill — taught in one clinical visit, refined over the first few self-administrations; the auto-injector pen format further reduces procedural complexity (Pattern Z.injection-framing).

Indication scope. Semaglutide carries the broadest indication scope of any GLP-1 RA as of 2026-05-13 — six FDA-approved-for-marketing-claims indications plus one investigational extension. FDA-approved for marketing claims for: type 2 diabetes (Ozempic 2017; Rybelsus 2019; pivotal program SUSTAIN-1 through -10 and PIONEER-1 through -10); chronic weight management in adults (Wegovy 2021; STEP-1 through -8); chronic weight management in adolescents ≥12 years (Wegovy 2022; STEP-TEENS); CV risk reduction in adults with T2D and established CVD (Ozempic 2020; SUSTAIN-6) and in adults with BMI ≥27 and established ASCVD without diabetes (Wegovy label expansion 2024; SELECT); MASH with F2–F3 fibrosis (Wegovy label expansion 2025; ESSENCE); CKD in T2D (Ozempic label expansion 2025; FLOW); the Wegovy HD 7.2 mg high-dose CWM extension (2026; STEP UP). Investigational extension: HFpEF with obesity (STEP-HFpEF / STEP-HFpEF-DM; label expansion pending sponsor submission).

When to reach for the [[Semaglutide Protocol]]. First-line for the broadest indication scope in the GLP-1-RA class. Specifically: T2D (any of the six FDA-approved indications); adolescent obesity ≥12 years (one of two pediatric-labeled options alongside liraglutide/Saxenda); CV risk reduction in established disease (one of three GLP-1-RA-class molecules with CVOT-positive primary endpoint, alongside liraglutide LEADER and dulaglutide REWIND); MASH F2–F3 (the first FDA-approved-for-marketing-claims MASH GLP-1 RA, following ESSENCE 2025); CKD in T2D (the first FDA-approved-for-marketing-claims kidney-composite GLP-1 RA, following FLOW 2025); patients preferring oral platform (Rybelsus, with PPI absorption considerations); patients valuing the established evidence base across the most indications. Alternatives to consider: tirzepatide for higher weight-loss magnitude in non-T2D obesity (SURMOUNT-5 head-to-head ~6.5 percentage points greater at max-tolerated dose) or for OSA-with-obesity (the only FDA-approved-for-marketing-claims OSA GLP-1-class therapy); liraglutide for daily-injection-preference, pediatric T2D ≥10 years (not covered by semaglutide), or pre-conception planning with shorter half-life washout; orforglipron for patients preferring oral non-peptide platform without absorption-enhancer fasting requirement (pre-approval; ACHIEVE / ATTAIN program pending).

Structural notes. Semaglutide is the Wave 1 lead exemplar in the protocol library — the calibration baseline subsequent canonicals mirror. The [[Semaglutide Protocol]] is the longest and most fully populated per-canonical protocol (~1,900 lines). It is the recommended first read for a clinician new to the library (orientation step 2 per §1.3 above).

3.2 Tirzepatide — [[Tirzepatide Protocol]]

Compound. Tirzepatide is a 39-amino-acid synthetic peptide engineered by Eli Lilly as a long-acting dual agonist at the GIP receptor and the GLP-1 receptor (Coskun 2018 Mol Metab PMID 30473097). Biased-affinity profile: GIPR at native-GIP-like affinity; GLP-1R at ~5-fold lower affinity than native GLP-1. Half-life ~5 days enables once-weekly SC injection. Marketed as Mounjaro (T2D) and Zepbound (CWM and OSA-with-obesity). There is no approved oral tirzepatide platform as of 2026-05-13; oral development would require either an absorption-enhancement formulation (analogous to SNAC for oral semaglutide) or a non-peptide small-molecule structure (analogous to orforglipron).

Indication scope. FDA-approved for marketing claims for: T2D (Mounjaro 2022; SURPASS-1 through -5); chronic weight management (Zepbound 2023; SURMOUNT-1 through -5); moderate-to-severe OSA with obesity (Zepbound December 2024; SURMOUNT-OSA). In development / investigational: MASH (SYNERGY-NASH Phase 2 PMID 38856224 reported ~62% MASH resolution at 15 mg vs ~10% placebo; Phase 3 program in development); HFpEF with obesity (SUMMIT Phase 3 PMID 39555826 reported HR ~0.62 for CV death or worsening HF events); CV outcomes (SURMOUNT-MMO NCT05556512 Phase 3 ACTIVE_NOT_RECRUITING, primary completion 2027-10); kidney outcomes (in development).

When to reach for the [[Tirzepatide Protocol]]. First-line for: T2D (the dual GIP/GLP-1 mechanism produces incremental HbA1c reduction beyond single-receptor GLP-1 RAs at comparable doses — SURPASS-2 head-to-head vs semaglutide demonstrated ~0.5 percentage point greater HbA1c reduction at 15 mg); chronic weight management in adults where higher weight-loss magnitude is the clinical priority (SURMOUNT-5 max-tolerated-dose head-to-head: tirzepatide −20.2% vs semaglutide −13.7% at week 72); moderate-to-severe OSA with obesity (the only FDA-approved-for-marketing-claims OSA GLP-1-class therapy as of 2026-05-13). Ophthalmologic class-differentiation consideration: Lawrenson 2025 PMID 40383360 (Lakhani et al Am J Ophthalmol; 180-country FAERS + WHO VigiBase pharmacovigilance) documented ION/NAION signal-presence for semaglutide and signal-absence for tirzepatide at the same analytical threshold; post-approval exposure-window asymmetry caveat applies (semaglutide ~82 months vs tirzepatide ~28 months at study cutoff September 2024); absent-signal-at-threshold does not equal absent-signal-in-population. Alternatives: semaglutide for broader indication scope (MASH approved; CKD approved; oral platform available); retatrutide (pre-approval) for upper-magnitude weight-loss consideration in the TRIUMPH program research-state; survodutide (pre-approval) for glucagon-axis-distinct dual coagonist consideration.

Structural notes. Tirzepatide is a Wave 1 canonical and the dual-receptor-coagonist structural exemplar. The protocol is the recommended second read for a clinician new to the library (orientation step 3 per §1.3 above). Pattern N.1 enforcement at protocol structure: tirzepatide is a peptide, not a small molecule; the protocol lives at /Protocols/ under the peptides folder hierarchy.

3.3 Retatrutide — [[Retatrutide Protocol]]

Compound. Retatrutide is a synthetic peptide engineered by Eli Lilly as a triple coagonist at the GIP receptor, the GLP-1 receptor, and the glucagon receptor (Coskun 2022; Phase 1 first-in-human; Phase 2 TRIUMPH-1 readout 2023). The glucagon-axis activation distinguishes retatrutide from tirzepatide’s dual GIP/GLP-1 mechanism — glucagon-receptor activation is hypothesized to contribute incremental energy-expenditure-mediated body-weight reduction beyond the GIP/GLP-1-axis appetite and gastric-emptying mechanisms. Once-weekly SC injection.

Indication scope. Pre-FDA-approval-for-marketing-claims for any indication. Pattern AA enforcement: retatrutide is investigational, not “approved-pending” or “next-generation FDA drug.” TRIUMPH program reading out across multiple indications:

TRIUMPH-1 (obesity Phase 2; Jastreboff 2023 NEJM PMID 37354645): ~24% body-weight loss at 12 mg / 48 weeks; the largest Phase 2 obesity weight-loss magnitude in the GLP-1-class era.
TRIUMPH-2 (T2D Phase 2)
TRIUMPH-3 (obesity with CV risk Phase 3)
TRIUMPH-4 (obesity Phase 3): sponsor topline December 2025 reported ~28.7% body-weight loss at 12 mg.
TRIUMPH-MASH (MASH; in development)

When to reach for the [[Retatrutide Protocol]]. This protocol is the reference for a clinician whose patient is asking about retatrutide (the Phase 2 NEJM magnitude generated substantial patient-level inquiry) or whose patient is candidate for clinical-trial enrollment in the TRIUMPH program. Pre-FDA-approval-for-marketing-claims means: retatrutide is not commercially available outside trial enrollment; compounded retatrutide formulations have appeared in 503A and 503B compounding pathways but represent a research-state preparation, not an FDA-approved formulation. The protocol’s §10 patient-counseling beats include the Pattern AA / Pattern Z.research-precision-compliant frame for the patient asking “should I switch to retatrutide?” — the answer is research-state precision (Phase 3 program reading out; FDA submission pathway pending; not commercially available outside trial enrollment) plus a fact-based comparator framing against the approved compounds. Alternatives — for any patient where the clinical decision is between an approved and an investigational compound, the approved compounds (tirzepatide, semaglutide) are the operational first-line; retatrutide enters consideration when Phase 3 data and FDA-approval-for-marketing-claims state advance.

Structural notes. Retatrutide is a Wave 1 canonical; the protocol mirrors the semaglutide structural template with calibration to a pre-approval evidence base. Pattern Z.research-precision is load-bearing throughout — bias-vocabulary like “highly experimental” is replaced with research-state precision (trial names, magnitudes, NCT identifiers, readout state).

3.4 Survodutide — [[Survodutide Protocol]]

Compound. Survodutide (BI 456906) is a synthetic peptide co-developed by Boehringer Ingelheim and Zealand Pharma as a dual coagonist at the glucagon receptor and the GLP-1 receptor. The glucagon-axis activation distinguishes survodutide from tirzepatide’s GIP-axis activation — the two dual coagonists represent distinct dual-mechanism families. Once-weekly SC injection.

Indication scope. Pre-FDA-approval-for-marketing-claims for any indication. SYNCHRONIZE program reading out:

SYNCHRONIZE-1 / -2 (obesity Phase 3)
SYNCHRONIZE-NASH (MASH Phase 3; NCT06632327)
Phase 2 obesity (Le Roux 2024 PMID 38446694) reported ~19% body-weight loss at 4.8 mg / 46 weeks.

When to reach for the [[Survodutide Protocol]]. Reference for the clinician whose patient is asking about survodutide or who is considering Phase 3 trial enrollment. The glucagon-axis-distinct mechanism is the protocol’s structural anchor: §1 indication scope frames the dual-receptor pharmacology including the hepatic-glucose-output considerations (glucagon-axis activation has theoretical hepatic-glucose-output implications relevant to T2D-coexistent populations and MASH-phenotype populations); §6 AE management algorithms reflect dual-mechanism AE profile with glucagon-axis-specific considerations. Pre-FDA-approval-for-marketing-claims means: not commercially available outside trial enrollment; the protocol’s §10 patient-counseling beats anchor research-state precision. Alternatives — for clinical decision in approved-compound space, semaglutide (with MASH approval) is the operational first-line for MASH-phenotype patients; tirzepatide (with broader CWM approval) is the operational first-line for non-MASH obesity. Survodutide enters consideration when Phase 3 SYNCHRONIZE readouts advance and FDA-approval-for-marketing-claims state changes.

Structural notes. Survodutide is a Wave 2 canonical. The protocol is calibrated to pre-approval evidence density per Editorial Framework §1.6 — tighter than semaglutide’s six-indication protocol, fuller than retatrutide’s earlier-phase Phase 2 evidence state.

3.5 Liraglutide — [[Liraglutide Protocol]]

Compound. Liraglutide is the class-foundational GLP-1 RA — the first GLP-1 RA to receive FDA approval for T2D (Victoza 2010) and for chronic weight management (Saxenda 2014). 30-amino-acid peptide with C16 fatty-acid acylation enabling albumin binding and a 13-hour half-life supporting once-daily SC administration. Two marketed formulations: Victoza (T2D; dosing up to 1.8 mg daily) and Saxenda (CWM; dosing up to 3.0 mg daily). The once-daily injection cadence differentiates liraglutide from the weekly-injection cadence of semaglutide, tirzepatide, retatrutide, survodutide, cagrilintide, CagriSema, and IcoSema.

Indication scope. FDA-approved for marketing claims for: T2D in adults (Victoza, January 25, 2010; LEAD-1 through -6); chronic weight management in adults (Saxenda, December 23, 2014; SCALE-Obesity-and-Prediabetes, SCALE-Maintenance, SCALE-Diabetes, SCALE-Sleep-Apnea); CV risk reduction in T2D with established CVD (Victoza label expansion, August 25, 2017; LEADER NCT01179048 reported HR 0.87 for three-point MACE at median 3.8 years); pediatric T2D ≥10 years (Victoza label expansion, June 17, 2019; ELLIPSE trial); chronic weight management in adolescents ≥12 years with body weight >60 kg and BMI ≥95th percentile age-and-sex-adjusted (Saxenda label expansion, December 4, 2020; SCALE-Teens); insulin degludec + liraglutide fixed-ratio combination for T2D (Xultophy 100/3.6, November 21, 2016; DUAL program). Multiple FDA-approved generic ANDAs 2024–2025 (off-patent transition).

When to reach for the [[Liraglutide Protocol]]. First-line for: pediatric T2D ≥10 years (the only FDA-approved-for-marketing-claims GLP-1 RA for this indication as of 2026-05-13); patients who prefer daily injection cadence over weekly (a minority preference but a real one for patients who anchor adherence to daily routines); pre-conception planning where the shorter half-life supports faster washout — Section 8 discontinuation arithmetic differs from weekly compounds (liraglutide ~13-hour half-life; ~5 half-lives = ~3 days for substantial clearance versus semaglutide ~7-day half-life; ~5 half-lives = ~35 days); patients on liraglutide-stable therapy who do not have a clinical reason to switch (the “if it ain’t broke” calibration). Alternatives — for non-pediatric T2D and non-pediatric CWM, the weekly-injection compounds (semaglutide, tirzepatide) generally produce greater magnitude-of-effect (semaglutide CWM weight loss ~14.9% vs liraglutide CWM weight loss ~8.0%; tirzepatide CWM weight loss ~20.9%). Liraglutide’s class-foundational position remains important — clinicians who learned GLP-1 RA pharmacology on liraglutide carry the mechanism framework forward.

Structural notes. Liraglutide is a Wave 3 #1 canonical. The protocol calibrates against the deepest CV-outcomes evidence base in the class (LEADER was the first CV-positive GLP-1 RA CVOT, anchoring the class-effect framing) and against the pediatric T2D + adolescent obesity indication uniqueness in the class.

3.6 Cagrilintide — [[Cagrilintide Protocol]]

Compound. Cagrilintide is a long-acting amylin receptor agonist developed by Novo Nordisk. Synthetic peptide based on the human amylin sequence with acylation and stabilization for once-weekly SC administration. The amylin axis is mechanistically distinct from the GLP-1 axis — amylin reduces postprandial glucose excursion via glucagon suppression and slowed gastric emptying, with complementary appetite-reduction signaling. The mechanism distinction is load-bearing: cagrilintide is not “another GLP-1 RA” but an amylin analog with its own receptor pharmacology and AE profile.

Indication scope. Pre-FDA-approval-for-marketing-claims as monotherapy. Phase 2 monotherapy data (Lacefield 2024; Frias 2023) reported ~10% body-weight loss at 4.5 mg / 26 weeks — a magnitude smaller than the GLP-1 RA class but with a different AE profile (lower GI AE burden in head-to-head comparison; amylin-class AEs including nausea, hypoglycemia in T2D-coexistent populations). The development pathway is via the CagriSema combination product (cagrilintide + semaglutide) — the REDEFINE Phase 3 program (REDEFINE-1, -2, -3) is the registration-evaluated combination.

When to reach for the [[Cagrilintide Protocol]]. Reference for the mechanism precision (amylin receptor pharmacology; the load-bearing class distinction from GLP-1 RAs) and for understanding the cagrilintide partner in the CagriSema combination. As monotherapy, cagrilintide is pre-FDA-approval-for-marketing-claims; clinical use outside trial enrollment is not commercially routed. The protocol’s §10 patient-counseling beats anchor research-state precision and the explanation of why the combination product (CagriSema) is the registration pathway. Alternatives — for patients seeking pharmacologic weight-loss therapy in the amylin class, the operational pathway is CagriSema rather than cagrilintide monotherapy.

Structural notes. Cagrilintide is a Wave 2 canonical. The protocol is calibrated tighter than the GLP-1 RA canonicals per Editorial Framework §1.6 (phenotype-narrower scope; pre-approval evidence state; combination-pathway-anchored development).

3.7 CagriSema — [[CagriSema Protocol]]

Compound. CagriSema is the fixed-ratio combination of cagrilintide (long-acting amylin analog) and semaglutide (long-acting GLP-1 RA), co-administered as a single once-weekly SC injection. The combination mechanism layers amylin-axis appetite reduction and gastric-emptying slowing onto GLP-1-axis appetite reduction and glycemic control. The combined AE profile is structurally distinct from semaglutide monotherapy — early Phase 2 data suggested the cagrilintide component may attenuate GLP-1-RA-mediated GI AE during early titration, though Phase 3 REDEFINE-program data are the load-bearing evidence base.

Indication scope. Pre-FDA-approval-for-marketing-claims. REDEFINE Phase 3 program:

REDEFINE-1 (obesity; sponsor topline 2025): ~22.7% body-weight loss at 68 weeks (the upper magnitude in the approved + late-stage CWM space, comparable to tirzepatide SURMOUNT-1 at ~22.5%)
REDEFINE-2 (obesity with T2D; sponsor topline 2025): ~13.7% body-weight loss — the smaller magnitude in the T2D phenotype mirrors the STEP-1-vs-STEP-2 magnitude pattern for semaglutide monotherapy
REDEFINE-3 (obesity with established CVD; CV outcomes; in progress)

When to reach for the [[CagriSema Protocol]]. Reference for the combination-product mechanism and the REDEFINE evidence base. Pre-FDA-approval-for-marketing-claims means: CagriSema is not commercially available outside trial enrollment; the protocol’s §10 patient-counseling beats anchor research-state precision. The protocol’s structural value pre-approval is in the comparator framing — clinicians evaluating the magnitude-of-effect landscape across approved (semaglutide, tirzepatide) and late-stage pre-approval (CagriSema, retatrutide, survodutide) compounds use the protocol to triangulate. Alternatives — operational first-line in approved-compound space remains semaglutide (for the broader indication scope) or tirzepatide (for higher CWM magnitude and OSA indication).

Structural notes. CagriSema is a Wave 2 canonical. The protocol carries the combination-product Pattern AB.4 discipline at §11 (citation of both cagrilintide and semaglutide pivotal trials plus the REDEFINE combination-specific trials; sponsor-topline framing per Pattern AB.4 publication-type precision).

3.8 IcoSema — [[IcoSema Protocol]]

Compound. IcoSema is the fixed-ratio combination of once-weekly insulin icodec (an ultra-long-acting basal insulin analog with ~1-week half-life supporting once-weekly SC dosing) and semaglutide (long-acting GLP-1 RA), co-administered as a single weekly SC injection. The combination addresses the operational complexity of basal-insulin therapy in T2D patients requiring intensification — once-weekly dosing for both the basal insulin and the GLP-1 RA component reduces injection burden compared with daily basal insulin + weekly GLP-1 RA separate-injection regimens. The mechanism layer is basal-insulin glycemic control with GLP-1-RA-mediated post-prandial glucose control, appetite reduction, and the body-weight and CV-outcomes effects of the GLP-1 RA component. IcoSema is marketed in the European Union under the Novo Nordisk Kyinsu brand.

Indication scope (Pattern AA.marketing-claims-precise — dual-jurisdiction). EMA-approved-for-marketing-claims as Kyinsu (EC marketing authorization decision 24 November 2025) for T2D in adults whose condition remains inadequately controlled on either basal insulin OR a GLP-1 receptor agonist, used alongside diet, exercise, and oral antidiabetic medications. Pre-FDA-approval-for-marketing-claims in the US as of 2026-05-13; FDA submission status not publicly disclosed. Component-level regulatory state: insulin icodec FDA-approved-for-marketing-claims as Awiqli for T2D (2024-04-23); semaglutide FDA-approved-for-marketing-claims across multiple indications via Ozempic / Wegovy / Rybelsus.

COMBINE Phase 3 program:

COMBINE-1 (T2D vs basal-bolus icodec): demonstrated non-inferior HbA1c reduction with lower body weight and lower hypoglycemia
COMBINE-2 (T2D in basal-insulin-naive patients)
COMBINE-3 (T2D with prior basal-insulin therapy)

When to reach for the [[IcoSema Protocol]]. Reference for T2D patients requiring basal-insulin intensification where the operational simplification of weekly-only injection cadence is clinically meaningful. The protocol’s §1 indication scope frames the phenotype: T2D inadequately controlled on oral agents ± GLP-1 RA, requiring basal-insulin addition, where the patient’s adherence calculus favors weekly over daily injection. EU clinicians prescribe Kyinsu within the labeled EMA indication. US clinicians operate pre-FDA-approval-for-marketing-claims; the fixed-ratio combination is not commercially available in the US, and the available equivalent regimen is separate-injection Awiqli (insulin icodec, FDA-approved 2024 for T2D) + Ozempic (semaglutide, FDA-approved 2017 for T2D) with independent titration of each component per their respective FDA labels. The mechanism components are identical to IcoSema; the operational distinctions are injection burden (104 vs 52 injections/year) and titration flexibility (independent vs fixed-ratio). The protocol’s §10.6 Pattern Z anchor 5 frames the US pre-FDA-approval counseling beat. Alternatives — operational US first-line is daily basal insulin (degludec, glargine U-300) + weekly GLP-1 RA (semaglutide, tirzepatide) as separate injections; the operational simplification IcoSema offers when it reaches FDA approval is the integration into a single weekly injection, valuable for adherence-anchored patients but mechanistically equivalent.

Structural notes. IcoSema is a Wave 2 canonical. The protocol is the most phenotype-narrow per-canonical protocol in Tier 1 (T2D-only; basal-insulin-intensification-only). The protocol’s §6 AE management algorithms reflect the dual-mechanism AE profile including insulin-class hypoglycemia management and GLP-1-RA-class GI AE management.

3.9 Orforglipron — [[Orforglipron Protocol]]

Compound. Orforglipron is a non-peptide small-molecule oral GLP-1 receptor agonist developed by Eli Lilly. The non-peptide structure differentiates orforglipron from oral peptide GLP-1 RAs (oral semaglutide / Rybelsus, which uses the SNAC absorption enhancer and requires fasting pre-meal administration). Orforglipron’s oral bioavailability does not require an absorption enhancer and does not require fasting administration — operational characteristics that simplify daily oral dosing. Pattern N.1 enforcement at protocol structure: orforglipron is a small molecule (chemical synthesis), not a peptide (solid-phase peptide synthesis); the protocol’s compound-class framing throughout is non-peptide-small-molecule.

Indication scope. Pre-FDA-approval-for-marketing-claims for any indication. ACHIEVE program (T2D) and ATTAIN program (CWM) Phase 3 readouts 2025–2026:

ACHIEVE-1 (T2D; sponsor topline 2025): HbA1c reduction ~1.3–1.6 percentage points at 36 mg
ATTAIN-1 (CWM; sponsor topline 2025): ~11% body-weight loss at 36 mg / 72 weeks

Eli Lilly NDA submission process in progress.

When to reach for the [[Orforglipron Protocol]]. Reference for patients preferring oral platform without injection (a meaningful subset of patients for whom injection — despite Pattern Z.injection-framing precision that it is a routine clinical skill — remains a preference-anchored decision factor) and without the SNAC-mediated fasting-administration requirement of oral semaglutide. The protocol’s §1 indication scope frames the phenotype: oral-preference patient seeking GLP-1 RA pharmacology with single-receptor mechanism and once-daily oral dosing. Pre-FDA-approval-for-marketing-claims means: not commercially available outside trial enrollment as of 2026-05-13. Alternatives — operational first-line in oral GLP-1 RA space is Rybelsus (oral semaglutide; FDA-approved for marketing claims for T2D 2019; for CWM via oral Wegovy 25 mg 2025); operational first-line in non-oral GLP-1 RA space remains semaglutide (Ozempic / Wegovy) or tirzepatide.

Structural notes. Orforglipron is a Wave 3 #2 canonical. The protocol is the only Module 5 protocol structurally anchored to the small-molecule non-peptide path under Pattern N.1 — compound-class framing throughout reflects chemical-synthesis pharmacology rather than peptide-synthesis pharmacology; §6 AE management algorithms reflect oral small-molecule food-and-drug-interaction considerations rather than peptide-injection-site considerations; §9 combination rules reflect oral pharmacokinetic interaction profile.

3.10 Cross-canonical comparator framing — at-a-glance summary

Across the nine canonicals, the dominant compound-selection axes are:

Weight-loss magnitude (CWM indication; max-tolerated dose; head-to-head where available; cross-trial otherwise). Approximate ordering at max-tolerated dose: retatrutide ~28% (TRIUMPH-4) > tirzepatide ~20.9% (SURMOUNT-1) ≈ CagriSema ~22.7% (REDEFINE-1) > survodutide ~19% (Phase 2; SYNCHRONIZE pending) > semaglutide ~14.9% (STEP-1) ≈ semaglutide 7.2 mg ~18.7% (STEP UP) > orforglipron ~11% (ATTAIN-1) > liraglutide ~8.0% (SCALE) > cagrilintide monotherapy ~10% (Phase 2). The head-to-head data anchor is SURMOUNT-5 (tirzepatide vs semaglutide; PMID 40353578; ~6.5 percentage points favoring tirzepatide at max-tolerated dose week 72); other comparisons are cross-trial.
HbA1c reduction (T2D indication). At comparable doses: tirzepatide > semaglutide > orforglipron ≈ liraglutide; head-to-head SURPASS-2 (tirzepatide vs semaglutide) anchors the dual-vs-single comparison.
CV outcomes evidence. SUSTAIN-6 + SELECT (semaglutide; established CVD with T2D and without diabetes BMI ≥27); LEADER (liraglutide; T2D with established CVD); SURMOUNT-MMO (tirzepatide; Phase 3 ACTIVE_NOT_RECRUITING); REDEFINE-3 (CagriSema; in progress); SUMMIT (tirzepatide HFpEF).
MASH evidence. ESSENCE (semaglutide; FDA-approved for marketing claims 2025); SYNERGY-NASH (tirzepatide Phase 2 positive; Phase 3 in development); SYNCHRONIZE-NASH (survodutide Phase 3).
Kidney outcomes evidence. FLOW (semaglutide; FDA-approved for marketing claims 2025); kidney-outcomes programs in development for other compounds.
Ophthalmologic class-differentiation. Lawrenson 2025 PMID 40383360 documented ION/NAION signal-presence for semaglutide and signal-absence for tirzepatide at the same analytical threshold; the class-differentiation finding is hypothesis-generating, not class-wide.
Route and dosing cadence. Daily SC: liraglutide. Weekly SC: semaglutide, tirzepatide, retatrutide, survodutide, cagrilintide, CagriSema, IcoSema. Oral daily: Rybelsus (oral semaglutide; SNAC + fasting), oral Wegovy 25 mg (semaglutide CWM oral; 2025), orforglipron (small-molecule; no SNAC, no fasting).
Regulatory state. FDA-approved for marketing claims: semaglutide (6 indications), tirzepatide (3 indications), liraglutide (5 indications across adult and pediatric labels). Pre-FDA-approval-for-marketing-claims: retatrutide, survodutide, cagrilintide-monotherapy, CagriSema, IcoSema, orforglipron.
Phenotype-narrower indications. Pediatric T2D ≥10 years: liraglutide only. Pediatric CWM ≥12 years: liraglutide and semaglutide. OSA with obesity: tirzepatide only. MASH F2–F3: semaglutide only (as of 2026-05-13). CKD in T2D: semaglutide only (as of 2026-05-13).

The comparator framing above is reproduced in greater operational detail in §12 of each per-canonical protocol and in [[Module 5 – Phenotype-Guided Decision Tree Protocol]] §branch points.

§4 Adjunct protocols (the three)

The three adjunct protocols cover phenotype-narrow compound families that clinicians layer onto canonical GLP-1 RA / coagonist / amylin therapy when the canonical does not address a specific phenotype-narrow problem. Adjuncts are not first-line therapy in most patients on canonical therapy; the protocols specify which phenotype-narrow indications they target and which patients they do not apply to.

Pattern R.1 enforcement at this section: the adjunct protocols open with what the compound family does and for whom, not with what regulatory limits constrain it. Regulatory framing is precise (Pattern AA.marketing-claims) — most adjunct compounds are not FDA-approved for marketing claims for any drug indication and operate through 503A / 503B compounding pathways or cosmetic-grade classification — but the regulatory framing is scoped factual context, not deficit-leading frame for the indication.

4.1 Tesamorelin + AOD-9604 — [[Tesamorelin + AOD-9604 – Visceral Fat Adjunct Protocol]]

Compound family. Two peptides addressing the visceral-fat-specific phenotype:

Tesamorelin is a 44-amino-acid synthetic analog of human growth hormone-releasing hormone (GHRH), administered as 2 mg subcutaneous daily injection. Mechanism: GHRH-receptor agonism stimulates pulsatile endogenous growth hormone secretion from the anterior pituitary, restoring the physiologic GH-IGF-1 axis pattern. The visceral-adipose-tissue (VAT) reduction is mediated by GH-axis-driven lipolysis with VAT-preferential effect documented across the tesamorelin trial program. FDA-approved for marketing claims for HIV-associated lipodystrophy (Egrifta 2010; the pivotal Falutz program). Off-label use for non-HIV visceral adiposity and MASLD is supported by primary-source evidence — Stanley JAMA 2014 (PMID 25038357) randomized trial demonstrated VAT reduction and intra-hepatic lipid reduction in non-HIV obesity with MASLD; the Tesamorelin Body Composition Meta-Analysis (PMID 41545261) consolidates the body-composition evidence base.

AOD-9604 is a synthetic peptide based on the C-terminal lipolytic fragment of human growth hormone (residues 177–191 with a tyrosine modification). AOD-9604 was developed for obesity in the 1990s–2000s by Metabolic Pharmaceuticals; the Phase 2 obesity development program did not meet primary endpoint and development for the obesity indication terminated. AOD-9604 is not FDA-approved for marketing claims for any drug indication; injectable preparations are available through 503A compounding pharmacy pathways for off-label use; cosmetic-grade topical formulations exist. The evidence base is animal lipolysis-and-fat-oxidation studies (PMID 11146367; PMID 11713213), Phase 1 / Phase 2 human pharmacology (PMID 15134286; PMID 10950816), and practitioner-experience case series; RCT-level human evidence for the visceral-fat-specific weight-loss indication is research-state-incomplete.

When to reach for the [[Tesamorelin + AOD-9604 – Visceral Fat Adjunct Protocol]]. Three phenotype-narrow indications:

HIV-associated lipodystrophy. The FDA-approved-for-marketing-claims tesamorelin indication. Protocol §4 initiation reflects the Egrifta label dosing and monitoring (IGF-1 surveillance; glucose-tolerance monitoring as GH-axis activation has glycemic-effect implications).
Non-HIV visceral-fat-dominant obesity, with or without MASLD/MASH-pre-fibrotic phenotype. Off-label tesamorelin use supported by Stanley JAMA 2014 (PMID 25038357) and the body-composition meta-analysis. Reach for this protocol when the patient on canonical GLP-1 RA / coagonist therapy has documented subcutaneous-dominant weight loss but persistent visceral-fat phenotype (clinical sign: persistent abdominal girth disproportionate to total body-weight reduction; imaging or DXA documentation of visceral-to-subcutaneous fat ratio) and where VAT-specific reduction is the clinical priority.
AOD-9604 use case. Predominantly practitioner-experience-anchored off-label use for fat-reduction adjunct purposes. Pattern Z.research-precision enforcement: the protocol frames AOD-9604 in research-state precision — animal evidence base, terminated obesity development program, practitioner-experience literature, no Phase 3 human evidence for the weight-loss indication — without bias-vocabulary (“highly experimental” / “fringe” / “unproven” are Pattern Z violations). The clinician decides; the protocol presents the research state.

When the adjunct does NOT apply. Patients on canonical therapy achieving balanced weight loss with proportional visceral and subcutaneous reduction; patients without documented visceral-fat-dominant phenotype; patients in whom GH-axis activation is contraindicated (active malignancy on therapy — IGF-1 axis activation has theoretical risk implications; severe glucose intolerance — GH-axis activation has glycemic-effect implications; pregnancy / lactation — tesamorelin label-contraindicated; pediatric / adolescent — GH-axis activation interacts with growth-stage pharmacology).

Structural notes. The Tesamorelin component carries an FDA-approved-for-marketing-claims indication; the AOD-9604 component does not. The protocol carries dual-component regulatory framing throughout — §1 indication scope distinguishes the tesamorelin Egrifta indication from the broader off-label use cases; §11 source citations distinguish the FDA-approval-for-marketing-claims trials (Falutz program for HIV lipodystrophy) from the off-label use evidence (Stanley JAMA 2014; body-composition meta-analysis; AOD-9604 development literature). The protocol’s structural pattern is one protocol covering two compounds in the same phenotype-narrow indication family.

4.2 CJC-1295 + Ipamorelin + MOTS-c — [[CJC-1295 + Ipamorelin + MOTS-c – Lean Mass Preservation Stack Protocol]]

Compound family. Three peptides addressing the lean-mass-preservation-during-caloric-deficit-weight-loss phenotype:

CJC-1295 is a 30-amino-acid GHRH analog with two formulation variants — CJC-1295 with DAC (drug affinity complex; long-acting; weekly SC) and CJC-1295 without DAC (also called modified GRF 1-29 or Mod GRF 1-29; shorter half-life; daily or BID SC). Mechanism: GHRH-receptor agonism stimulates endogenous GH secretion; the DAC modification extends half-life via albumin binding. The variant distinction is load-bearing: with-DAC produces tonic GH-axis elevation; without-DAC preserves pulsatile physiologic GH secretion. Practitioner-stack convention typically pairs without-DAC CJC with ipamorelin to preserve pulsatile GH secretion patterns; with-DAC CJC stand-alone produces continuous-elevation pharmacology with distinct AE profile considerations.

Ipamorelin is a 5-amino-acid GHRP (growth hormone-releasing peptide) and ghrelin-receptor mimetic. Mechanism: ghrelin-receptor agonism stimulates GH secretion through a parallel pathway to GHRH; combined GHRH + GHRP (CJC + Ipamorelin) produces synergistic pulsatile GH release. Ipamorelin’s GHRP-class advantage is selectivity — it does not substantially activate the cortisol or prolactin axes that older GHRPs activate.

MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the 12S rRNA gene of the mitochondrial genome. Mechanism: MOTS-c regulates skeletal muscle insulin sensitivity, mitochondrial homeostasis, and exercise capacity through AMPK-axis signaling (Lee 2015 Cell Metab PMID 25738459; Reynolds 2021 FASEB J PMID 33473109). The Phase 2 / Phase 3 human evidence base for the lean-mass-preservation indication is research-state-incomplete (Pattern Z.research-precision enforcement: state the actual research base — Lee 2015 mechanism characterization; animal studies PMID 36677050, PMID 33473109; early human pharmacology — and let the clinician evaluate; do not bias-vocabulary).

Regulatory state across the three compounds. None of the three compounds is FDA-approved for marketing claims for any drug indication. All three are available through 503A compounding pharmacy pathways for off-label use. CJC-1295 and Ipamorelin are WADA-prohibited (S2.2 peptide hormones) for competitive athletes; the protocol’s §10 patient-counseling beats include a Pattern Z anchor for the competitive-athlete population. MOTS-c is investigational; the evidence base is the Lee 2015 Cell Metab mechanism paper plus animal studies plus early human pharmacology.

When to reach for the [[CJC-1295 + Ipamorelin + MOTS-c – Lean Mass Preservation Stack Protocol]]. Four phenotype-narrow indications:

Older adult ≥65 with sarcopenic-obesity phenotype. Caloric-deficit weight loss on canonical GLP-1 RA / coagonist therapy produces a lean-mass-loss fraction that varies by phenotype; older adults with baseline reduced lean mass are at risk of clinically meaningful sarcopenia progression. The lean-mass adjunct protocol layers GHRH-axis activation onto canonical therapy to attenuate lean-mass loss; the resistance-training and dietary-protein foundations are the load-bearing first-line interventions and the adjunct is the layered pharmacologic support.
High baseline lean mass / athletic populations. Patients whose body composition baseline includes high lean-mass-to-fat-mass ratio (athletes, regular resistance-training adherents) and whose weight-loss goal includes preserving athletic performance metrics. The protocol’s §1 indication scope frames the phenotype and the WADA-prohibition consideration.
Post-bariatric or post-GLP-1-RA rapid-weight-loss with DEXA-documented lean-mass reduction. Patients in whom canonical therapy has produced rapid weight loss with DEXA-quantified lean-mass-loss exceeding the patient’s tolerance threshold. The protocol’s §3 pre-treatment workup includes DEXA body composition (Tier 1 lab); §5 maintenance includes DEXA repeat cadence.
Patient request — fact-based shared decision-making. Patients reading peptide-therapeutics content (including patient-education content on Synergy and elsewhere) who arrive with a request for the lean-mass adjunct. The protocol’s §10 patient-counseling beats include the fact-based frame for the shared-decision conversation, anchored at Pattern Z.research-precision.

When the adjunct does NOT apply. Patients on canonical therapy achieving balanced weight loss with proportional preservation of lean mass (the typical phenotype on slow-titration GLP-1 RA / coagonist therapy with adequate dietary protein and resistance training); patients without DEXA-documented lean-mass-loss concern; patients in whom GH-axis activation is contraindicated (see §4.1 above; same considerations apply); active malignancy concerns (IGF-1 axis activation has theoretical risk implications); competitive athletes subject to WADA testing where the WADA-prohibition is decision-relevant.

Structural notes. The protocol carries three-compound regulatory framing throughout. The protocol’s §10 patient-counseling beats include Pattern Z anchors for: (a) compounded-peptide quality criteria conversation (anchors 1 + 2); (b) IGF-1 axis activation and cancer-risk patient question (anchor 3-aligned); (c) WADA-prohibition for competitive athletes; (d) MOTS-c research-state precision (anchor 5-aligned for the investigational compound framing); (e) lean-mass-loss-as-pseudo-plateau versus set-point-reset distinction (cross-references the canonical decision-tree protocol). The resistance-training-and-protein-intake foundation is framed throughout as the first-line lean-mass preservation strategy with the peptide adjunct as the layered pharmacologic support.

4.3 GHK-Cu — [[GHK-Cu – Post-Weight-Loss Skin Laxity Protocol]]

Compound. GHK-Cu is the copper-bound tripeptide form of glycyl-L-histidyl-L-lysine (GHK) — a naturally occurring human peptide first characterized in human plasma by Pickart in 1973. The copper-bound form (GHK-Cu) is the bioactive form across the documented mechanism literature: collagen and elastin synthesis stimulation in fibroblasts; wound-healing and tissue-remodeling effects; antioxidant and anti-inflammatory signaling. Three administration routes are documented in the practitioner literature and the cosmetic-industry evidence base:

Topical (cosmetic-grade and pharmaceutical-grade formulations; the dominant cosmetic-industry evidence base; widely commercially available)
Subcutaneous injection (off-label; 503A compounding pharmacy preparations; practitioner-experience literature)
Intradermal injection (off-label; clinician-administered; practitioner-experience literature)

Regulatory state. GHK-Cu is not FDA-approved for marketing claims for any drug indication. Topical cosmetic formulations are widely marketed under cosmetic-ingredient classification (not requiring drug approval). Injectable preparations are available through 503A compounding pharmacy pathways for off-label use. RCT-level human evidence for the post-weight-loss-laxity-specific indication is research-state-incomplete; the supporting evidence base is in vitro fibroblast collagen-synthesis data (Maquart 1988, 1993), animal wound-healing models (PMID 28370978; PMID 27517151), cosmetic-industry topical efficacy data, gene-expression and tissue-remodeling mechanism literature (PMID 18644225; PMID 25302294; PMID 35083444; PMID 39963574), and practitioner clinical experience.

When to reach for the [[GHK-Cu – Post-Weight-Loss Skin Laxity Protocol]]. Two phenotype-narrow indications:

Post-weight-loss skin laxity in patients who have achieved substantial weight loss on canonical therapy and present with cosmetic / functional skin-laxity complaint. The indication phenotype: patient on canonical GLP-1 RA / coagonist therapy has achieved >15% body-weight loss (or >25 kg absolute loss); skin-laxity complaint is dermatologic-cosmetic (visible loose skin; restricted-mobility folding; psychosocial body-image impact); body-contouring surgical consultation is either declined, deferred, or supplementary. The protocol frames GHK-Cu as a fact-based option in the integrated body-contouring-and-skin-care discussion that includes nutrition, hydration, resistance training, topical retinoids and peptide formulations, and surgical / device-based alternatives.
Chronologic skin aging — the cosmetic-industry-anchored use case. The dominant use case for topical GHK-Cu formulations across the cosmetic-industry evidence base. The protocol’s §1 indication scope frames this use as adjacent-to-Module-5 (skin aging is not the Module 5 weight-loss-and-metabolic indication) but operationally connected via the practitioner workflow.

When the adjunct does NOT apply. Patients with skin-laxity sufficient to warrant body-contouring surgical evaluation as the primary intervention (skin-laxity grade 3–4 by clinician assessment; functional-impairment-anchored complaint; substantial overhanging tissue requiring panniculectomy or abdominoplasty); patients with active skin infection or wound at the proposed administration site; patients with Wilson disease or other copper-metabolism disorders (theoretical concern with copper-containing peptide; clinician judgment); pregnancy / lactation (research-state-incomplete; clinician judgment).

Structural notes. GHK-Cu is the most phenotype-narrow adjunct in the Module 5 protocol library. The protocol is calibrated tightest per Editorial Framework §1.6 — phenotype-narrow scope; topical-and-injectable cosmetic-grade-and-503A regulatory framing; cosmetic-industry-anchored evidence base alongside the practitioner-experience injectable literature. The protocol’s §10 patient-counseling beats include Pattern Z anchors for (a) fact-based comparator framing against body-contouring surgical alternatives, topical-only cosmetic-grade alternatives, and energy-device-based skin-tightening alternatives; (b) research-state precision for the off-label injectable use case; (c) integrated framing of GHK-Cu within the broader post-weight-loss body-contouring conversation rather than as a stand-alone “skin tightening peptide” deficit-leading frame.

4.4 When NOT to use an adjunct — the calibration anchor

Across the three adjunct protocols, the general calibration anchor is: adjuncts are layered onto canonical therapy for phenotype-narrow indications the canonical does not address. Adjuncts are not first-line therapy; adjuncts do not substitute for canonical therapy; adjuncts do not apply to every patient on canonical therapy. The clinician’s evaluation:

Has the patient established a stable canonical therapy regimen (semaglutide, tirzepatide, liraglutide, or another approved or trial-enrolled compound at the appropriate dose and titration state)?
Has the patient achieved or is the patient progressing toward the weight-loss or metabolic-disease-control target?
Is there a documented phenotype-narrow indication the canonical does not address — visceral-fat-dominant residual phenotype (→ tesamorelin / AOD-9604 protocol); lean-mass-loss concern with DEXA documentation (→ CJC-1295 / Ipamorelin / MOTS-c protocol); post-weight-loss skin laxity complaint (→ GHK-Cu protocol)?
Is the proposed adjunct supported by the protocol’s §1 indication scope, §2 selection criteria, and §3 pre-treatment workup?
Are the regulatory framing considerations (compounded-formulation source; quality criteria; off-label use documentation; WADA prohibitions for athletes) addressed in the patient discussion per Pattern Z fact-based-frame discipline?

If the four criteria are met, the relevant adjunct protocol applies. If they are not met, the canonical therapy alone is the operational position.

§5 Phenotype-Guided Decision Tree

5.1 The decision-tree protocol at a glance

The [[Module 5 – Phenotype-Guided Decision Tree Protocol]] is the operational compound-selection algorithm for the Module 5 protocol library. It is the workhorse document for everyday encounter use — the document the clinician reaches for when sitting with a specific patient and asking which compound is first-line for this patient, with this phenotype, in this clinical context.

The decision tree operationalizes the choice across:

The nine canonical compounds (semaglutide, tirzepatide, retatrutide, survodutide, liraglutide, cagrilintide, CagriSema, IcoSema, orforglipron)
The three adjunct compound families (tesamorelin + AOD-9604 visceral-fat; CJC-1295 + Ipamorelin + MOTS-c lean-mass; GHK-Cu skin-laxity)
The M5.1 phenotype taxonomy (metabolic phenotype; adiposity distribution; appetite phenotype; energy-expenditure phenotype; comorbidity load; pharmacologic history; life-stage modifier)
The Pattern AA-precise regulatory state (FDA-approved-for-marketing-claims compounds vs pre-approval-investigational compounds; phenotype-specific FDA labels — pediatric T2D, pediatric obesity, OSA, MASH, CKD)

5.2 Decision-tree structural anchor — at-a-glance summary

The decision-tree protocol carries the Protocol Template’s 12-section + 3-appendix structure, applied to the decision-algorithm context rather than to a single compound. The structural anchor:

§1 Indication scope — frames the decision tree as covering all Module 5 indication categories (T2D glycemic control; CWM in adults; CWM in adolescents ≥12 years; pediatric T2D ≥10 years; CV risk reduction in established CVD; MASH F2–F3; CKD in T2D; OSA with obesity; HFpEF with obesity-investigational; lean-mass preservation; visceral-fat reduction; post-weight-loss skin laxity).
§2 Selection criteria — frames the decision-tree entry criteria: a patient with at least one Module 5 indication category present, who has completed Pepteon Academy clinician-education content or equivalent baseline framework, in a clinical setting where the relevant compounds are accessible.
§4 Initiation protocol — the core algorithm: the decision branches walking from patient presentation → indication-category mapping → canonical first-line selection → adjunct-layering decision → AE-driven and plateau-driven branch decisions.
§5 Maintenance protocol — re-evaluation cadence for compound-selection decisions; criteria for switching canonicals; criteria for adding or removing adjuncts.
§6 Side-effect management — AE-driven branch points in the decision tree (when an AE in one compound class triggers consideration of switching to a different compound class — e.g., severe GI intolerance to semaglutide may trigger consideration of switching to tirzepatide or to oral orforglipron or to liraglutide daily at lower-magnitude weight-loss expectation).
§7 Plateau and non-response algorithm — the second core algorithm: the decision branches walking from plateau or non-response on canonical X → diagnostic algorithm (true plateau vs pseudo-plateau; adherence verification; phenotype re-assessment) → therapeutic algorithm (dose intensification within canonical; switching canonicals; adding an adjunct; transitioning out of pharmacotherapy).
§10 Patient counseling beats — the integration-layer counseling beats for the compound-selection conversation: the patient asking “which compound should I take?”, “should I switch from X to Y?”, “should I add an adjunct?” The Pattern Z verbatim-anchor calibration is load-bearing throughout (anchors 1, 2, 3, 4, 5 all apply to compound-selection conversations).
§12 Clinical decision tree — the operational at-a-glance decision algorithm with branch points keyed to the phenotype-taxonomy dimensions.

5.3 Decision-tree primary branch points — orientation summary

The decision-tree protocol covers approximately twelve primary branch points. The orientation summary below names the branch points and links the structural decisions to the protocol; the operational specifics live in the protocol document.

Indication-category mapping (T2D vs CWM vs CV vs MASH vs CKD vs OSA vs HFpEF vs adjunct-only). First branch: which indication category dominates the patient’s presentation?
Pediatric vs adult. Patients <12 years are outside Module 5 protocol scope. Patients 12–17 years route to the pediatric-labeled subset (liraglutide pediatric T2D ≥10 years; semaglutide adolescent CWM ≥12 years; liraglutide adolescent CWM ≥12 years).
Pregnancy or pre-conception planning. Pregnancy is a hard discontinuation trigger across the GLP-1 RA / coagonist class; pre-conception planning is a structured-washout-arithmetic decision (~35 days for weekly compounds with ~7-day half-life; ~3 days for liraglutide with ~13-hour half-life).
Magnitude-of-effect prioritization (CWM-dominant). For patients whose primary indication is CWM and whose phenotype supports it, the magnitude-of-effect axis: max-tolerated-dose ranking retatrutide (pre-approval) > tirzepatide ≈ CagriSema (pre-approval) > semaglutide 7.2 mg (Wegovy HD) > semaglutide 2.4 mg (Wegovy) > orforglipron (pre-approval) > liraglutide.
Indication-specific approval state. For MASH F2–F3 → semaglutide (the only FDA-approved-for-marketing-claims MASH GLP-1 RA as of 2026-05-13). For CKD in T2D → semaglutide (the only FDA-approved-for-marketing-claims kidney-composite GLP-1 RA). For OSA with obesity → tirzepatide. For CV risk reduction in established CVD → semaglutide (broadest indication; T2D and non-T2D BMI ≥27) or liraglutide (T2D + established CVD) or tirzepatide (HFpEF + obesity; SUMMIT) depending on phenotype subtype.
Route and dosing-cadence preference. Oral vs SC injection; daily vs weekly. Oral SC = Rybelsus (semaglutide; SNAC + fasting) or oral Wegovy 25 mg (semaglutide CWM) or orforglipron (pre-approval; non-peptide; no SNAC, no fasting). Daily SC = liraglutide. Weekly SC = semaglutide, tirzepatide, retatrutide (pre-approval), survodutide (pre-approval), cagrilintide (pre-approval), CagriSema (pre-approval), IcoSema (pre-approval).
AE-driven branch. Severe GI intolerance to one compound triggers consideration of switching to a different mechanism class (single-receptor GLP-1 RA → dual GIP/GLP-1 with potentially attenuated GI AE → amylin-axis combination CagriSema with cagrilintide attenuation of early-titration GI AE). Class-differentiated AE (NAION ophthalmologic signal per Lawrenson 2025) routes the patient with relevant ophthalmologic risk factors toward tirzepatide rather than semaglutide.
Plateau / non-response algorithm. True plateau vs pseudo-plateau (Pattern V direction-of-effect verification — is the plateau in absolute body weight reflecting set-point-reset, in DEXA-fat-mass, or in waist circumference?). Dose intensification within canonical; switching canonicals; adding adjunct (lean-mass preservation; visceral-fat reduction); de-prescribing.
Comorbidity-load branch. Polycondition phenotype (T2D + MASH + CKD + ASCVD) → semaglutide is the single compound covering all four indications. Monocondition phenotype → indication-specific first-line selection.
Adjunct-layering decision. Visceral-fat-dominant phenotype → [[Tesamorelin + AOD-9604 – Visceral Fat Adjunct Protocol]]. Lean-mass-loss concern with DEXA documentation → [[CJC-1295 + Ipamorelin + MOTS-c – Lean Mass Preservation Stack Protocol]]. Post-weight-loss skin-laxity complaint → [[GHK-Cu – Post-Weight-Loss Skin Laxity Protocol]].
Compounded-vs-FDA-approved decision. Pattern Z anchors 1 + 2 apply throughout. For compounds in active FDA-declared shortage at the time of the decision, 503A and 503B compounding pathways are real-world clinical options used by substantial patient populations; the protocol §10 Pattern Z verbatim-anchor frames the conversation. For compounds not in shortage, the FDA-approved formulation is the operational first-line; compounded formulations operate in a narrower regulatory and operational space.
Trial-enrollment vs commercial-therapy decision. For pre-FDA-approval-for-marketing-claims compounds (retatrutide; survodutide; cagrilintide-monotherapy; CagriSema; IcoSema; orforglipron), trial enrollment may be a meaningful patient-decision option. The protocol’s §10 Pattern Z.research-precision anchor frames the conversation in research-state terms.

5.4 When to reach for the decision-tree protocol vs a per-canonical protocol

Reach for the decision tree when the question is which compound or whether to switch compounds or whether to add an adjunct. The decision tree is the orientation document for the compound-selection step.

Reach for the per-canonical protocol when the compound has been selected and the question is operational — what is the initiation dose, what is the titration cadence, what is the AE-management algorithm for the AE the patient is experiencing, what is the maintenance dose, what is the discontinuation arithmetic. The per-canonical protocol is the operational document for compound use.

Reach for the canonical (Layer 3 at /obsidian-peptides/Peptides/[Compound].md) when the question is evidence-grade — what is the specific trial design that anchors the indication, what is the primary endpoint definition, what is the publication state and Pattern AB.4 verification of a specific finding. The canonical is the deep-evidence document for evidence triangulation.

The three documents work together; the decision tree is the entry point into the operational layer.

§6 Methodology + Pattern discipline

6.1 The five Pattern families load-bearing across Module 5

Every protocol in the Module 5 library is built against the AC2-26 Pattern catalog ([[AC2-26 – System Observations]]). The five Pattern families and their sub-patterns load-bearing across Module 5. As of the v2 refresh (2026-05-13), the sub-pattern roster includes five sub-patterns codified during the Module 5 production cycle — V.metric-axis, V.estimand-axis, AA.marketing-claims, Z.injection-framing, Z.research-precision — all cross-referenced in [[Synergy Editorial Framework]] v1.2 §1.2.1 (AA.marketing-claims) and §1.4 loaded-vocabulary table (Z.injection-framing + Z.research-precision):

Pattern R / R.1 / R.2 — anti-deficit-leading framing

The principle. Lead with what the molecule does and for whom, not with what it does not do, who it excludes, or what regulatory limits constrain it. Indication scope (Section 1 of every protocol) is the design-time-locked anchor; exclusions, contraindications, and regulatory framing live in their dedicated sections (Section 2; Section 11; Section 8 for pregnancy discontinuation).

Operational anchors.

R — anti-deficit-leading at the protocol architecture level. Section 1 indication scope opens with what the molecule does. Section 2 selection criteria opens with inclusion criteria (positive — who the molecule is for) before exclusion and contraindication.
R.1 — anti-deficit-leading at the section / paragraph / sentence level. Within any section, lead sentence presents the positive content; deficit content lives in scoped factual context after the positive lead.
R.2 — design-step enforcement. Indication scope is locked at the section-architecture-design step, before content generation. A protocol that drifts indication scope mid-draft (e.g., starts as “chronic weight management” and finishes as “T2D + chronic weight management + CV risk reduction”) signals that the design step was not enforced.

How to read this in a protocol. Section 1 opens with “the molecule is X; its FDA-approved-for-marketing-claims indication scope is Y; its phenotype primary targets are Z.” It does not open with “the molecule is not approved for pregnancy” or “the molecule has a boxed warning” — those facts are present in Sections 2 and 11.

Pattern V / V.metric-axis / V.estimand-axis — direction-of-effect verification

The principle. Every claim about effect direction (positive endpoint, negative endpoint, neutral signal) traces to a specific trial sub-population and is not over-generalized to populations outside the trial enrollment. A signal in one sub-population (e.g., retinopathy progression in patients with rapid HbA1c improvement and pre-existing advanced DR per SUSTAIN-6) is not extended to the overall trial population (the broader semaglutide patient population without advanced DR).

Operational anchor. When a protocol presents an effect direction — positive or negative or neutral — the protocol specifies the sub-population the effect was observed in, the trial that documented it, and the population the effect is NOT claimed for. Direction-of-effect verification prevents the recurring drift where “the trial showed X” becomes generalized to “the drug does X in all patients.”

Sub-patterns (discovered during Module 5 Stage 4 Sub-Audit B, 2026-05-13; applies vault-wide):

Pattern V.metric-axis — per-arm absolute change vs between-group treatment effect disclosure. Effect-size citations must specify which metric is being reported: per-arm absolute change (e.g., “−8.0% liraglutide vs −2.6% placebo” — both arms’ absolute change disclosed) versus between-group treatment effect (e.g., “estimated treatment difference −5.4 percentage points”) versus only one arm’s absolute change (which obscures the comparator). The metric-disclosure species of Pattern V’s effect-size-anchoring discipline. Forward-looking application: every effect-size citation in Module 5 protocols carries the per-arm and between-group metric-axis disclosure.
Pattern V.estimand-axis — treatment-policy vs treatment-regimen vs efficacy estimand disclosure. Trials with dual-estimand reporting (SURMOUNT-1 treatment-regimen estimand vs efficacy estimand; OASIS 4 treatment-policy vs adherent population; STEP UP regulatory-summary vs trial-primary) require estimand-axis disclosure when citing the effect size. The sibling sub-pattern to V.metric-axis. Forward-looking application: when a trial reports two estimands, every protocol citation specifies which estimand the magnitude reflects.

How to read this in a protocol. Effect-size claims throughout the protocol carry a sub-population qualifier — “in patients enrolled in [trial] with [enrollment criteria]” — and the effect-direction claim is scoped to that sub-population. The protocol does not claim effects in populations the trial did not enroll without explicit “research-state-incomplete” / “direction-of-effect not established” Pattern V framing. Metric-axis disclosure (“per-arm: −X% vs −Y%; between-group treatment difference: −Z percentage points”) and estimand-axis disclosure (“treatment-regimen estimand” / “treatment-policy estimand” / “efficacy estimand”) are visible alongside the magnitudes.

Pattern W — cross-section consistency

The principle. The same fact framed identically across the protocol. A mechanism statement in §1, an AE-class statement in §6, and a counseling beat in §10 that all anchor to the same primary source must frame the source consistently — same magnitude, same primary endpoint, same sub-population.

Operational anchor. Cross-section consistency is enforced at the verification gate (Appendix A of every protocol): the byte-count audit checks for cross-section divergence; the four-step verification cycle includes a Pattern W standing scan.

How to read this in a protocol. When reading §6 AE management and §10 patient counseling, the operational facts (effect magnitude, dose, frequency) should match the §1 indication scope and §11 source citations. If they diverge, that is a Pattern W violation surface — verification gate catches it pre-publication.

Pattern Z — steering-direction test

The principle. “The canonical presents facts. It does not steer clinical decisions.” (AC2-26 System Observations, Pattern Z.) Operational test: “Does this content present facts about [clinical option / safety question / comparator / patient question] and let the clinician decide, or does it steer the clinician toward / away from a clinical option?”

Operational anchor. Section 10 of every protocol (patient counseling beats) passes verbatim-anchor calibration against the five anchors at /Internal/Module-5-Pipeline/pattern-z-calibration-anchor.md:

Anchor 1 — Compounded-formulation operational characteristics. Compounded compounds are real-world clinical options used by substantial patient populations; operational differences from FDA-approved formulations framed neutrally (factual scope, not deficit framing).
Anchor 2 — Compounded-vs-FDA-approved patient-counseling beat. Patient question framed neutrally; counseling beat opens with affirmation; acknowledges differences as real without framing as deficits; closes with shared-decision-making invitation.
Anchor 3 — Pregnancy considerations research-state-leading section structure. Leads with research-state data (Parker 2025 pooled pregnancy review); standard clinical practice framed as factual (discontinue upon pregnancy awareness; ~5-half-life arithmetic); animal data + Category X-equivalent contraindication scoped after the research-state lead.
Anchor 4 — Comparator framing (e.g., tirzepatide vs semaglutide). Multi-dimensional fact presentation (weight magnitude, CV evidence, MASH, kidney, NAION class-differentiation, GI tolerability, cost, route); each dimension presented neutrally with primary-source anchoring; counseling beat opens with affirmation of both compounds.
Anchor 5 — Off-label adjunct framing (e.g., tesamorelin off-label for non-HIV visceral fat). Research-state precision (primary-source-supported off-label use; specific trial citations; magnitude-of-effect; sub-population); shared-decision-making invitation.

Sub-patterns (Dr. Gross 2026-05-13 M5.1 NotebookLM audio feedback):

Z.injection-framing — Self-injection is a routine clinical skill, not a daunting barrier. Patient-counseling beats for injectable therapeutics that frame self-injection as scary, daunting, intimidating, a major barrier, or a significant challenge are Pattern Z violations. Anchor framing: routine clinical skill; taught in one clinical visit; refined over the first few self-administrations; auto-injector pens further reduce procedural complexity.
Z.research-precision — Bias-vocabulary like “highly experimental” / “fringe” / “unproven” / “speculative” / “untested” applied to investigational compounds or off-label uses is a Pattern Z violation. Replace with research-state precision: name the trial(s), name the magnitudes, name the readout state, name the publication.

How to read this in a protocol. Section 10 patient-counseling beats are written in verbatim style — they are the actual scripts the clinician delivers to the patient, mirrored against the five anchor templates. If a counseling beat steers (toward or away from a clinical option), it fails Pattern Z calibration; the verification gate catches this pre-publication.

Pattern AA / AA.marketing-claims — regulatory-state precision

The principle. Every regulatory-state claim is precise. “FDA-approved for marketing claims for [indication X]” is the load-bearing phrasing. The full convention:

First-mention contexts use the full expansion. Section openers, headlines, table headers, executive summaries, FAQ openers, patient-counseling beats — expand to “FDA-approved for marketing claims for [indication X].”
Subsequent mentions in the same section may abbreviate to “FDA-approved” with the indication already established.
Cross-indication discussions always use the full convention. “FDA-approved for marketing claims for [X]; off-label for [Y]” when both registers apply.
Pre-approval compounds are framed in their research-state — Phase 3 program name, sponsor topline magnitudes, NCT identifiers — per Pattern Z.research-precision.

Operational anchor. Pattern AA precision is checked at the verification gate. The standing-scan catches “FDA-approved” without indication-anchoring (which imports drug-level claims that are indication-level facts) and “not FDA-approved” deficit-leading frames without scoped factual context.

How to read this in a protocol. Every FDA-approval claim names the indication, the brand name (where applicable), and the year of approval. “FDA-approved” is shorthand the protocol explicitly defines (in the opening Purpose block) as “FDA-approved for marketing claims for [indication X].”

6.2 Pattern AB.1 / AB.2 / AB.4 — identifier-integrity standing scans

The principle. Every NCT identifier, every PMID, every sponsor-to-trial linkage, every publication-type designation traces to verified primary sources.

AB.1 — Internal consistency of identifier-to-content mapping (the NCT identifier in §1 and the NCT identifier in §11 reference the same trial).
AB.2 — Sponsor-to-trial linkage accuracy.
AB.4 — Publication-type accuracy. A “Phase 3 RCT” claim must have a corresponding Phase 3 RCT publication, not a sponsor topline or press release; a “sponsor topline” or “press release” claim is framed as such, not promoted to “RCT publication” precision.

Operational anchor. AB.1 / AB.2 / AB.4 standing scans run at the verification gate. The tirzepatide v1.0 PSV iteration 1 surfaced an AB.4 publication-type failure (a press-release-derived magnitude framed as a Phase 3 RCT result); the standing scan now catches this pre-publication.

How to read this in a protocol. Source citations (§11) carry the publication-type designation. A sponsor topline cited as a magnitude anchor reads “(sponsor topline 2025)” not “(Phase 3 RCT 2025).” A press release cited as an indication anchor reads “(press release 2025)” not “(RCT publication 2025).”

6.3 Pattern N.1 — small-molecule path

The principle. Module 5 includes compounds from two structural classes: peptides (semaglutide, tirzepatide, retatrutide, survodutide, liraglutide, cagrilintide, CagriSema, IcoSema, tesamorelin, AOD-9604, CJC-1295, ipamorelin, MOTS-c, GHK-Cu) and small molecules (orforglipron). The two classes have distinct manufacturing pharmacology (solid-phase peptide synthesis vs chemical synthesis), distinct route options (peptide oral platforms require absorption enhancers; small-molecule oral platforms do not), and distinct combination-product considerations.

Operational anchor. Pattern N.1 enforces compound-class precision at file-system placement, compound-class framing throughout the protocol, mechanism-precision-driven section architecture, and the small-molecule-vs-peptide distinction in §1 indication scope and §6 AE management algorithms.

How to read this in a protocol. Orforglipron protocol carries Pattern N.1 enforcement throughout — small-molecule-non-peptide-oral-GLP-1R-agonist framing. The other eight canonicals plus the three adjunct families carry peptide-class framing.

6.4 Why protocols carry this discipline

The Pattern discipline is not bureaucratic overhead. Each Pattern operationalizes a specific failure mode the Pepteon Academy production pipeline encountered in early iterations:

Pattern R / R.1 / R.2 prevents the recurring drift toward deficit-leading framing that steers clinicians away from molecules before they have read the inclusion case.
Pattern V prevents the recurring drift toward over-generalization of trial findings to populations the trial did not enroll.
Pattern W prevents the recurring drift toward cross-section divergence where the same fact gets framed differently in §1, §6, and §10.
Pattern Z prevents the recurring drift toward steering — the failure mode Dr. Gross flagged most pointedly in the v1.0 semaglutide iteration (“There was a scary part about avoiding compounding pharmacies and doing it yourself. We need to tweak that significantly.”).
Pattern AA / AA.marketing-claims prevents the recurring drift toward imprecise regulatory-state claims that import drug-level approval where the actual claim is indication-level approval.
Pattern AB.1 / AB.2 / AB.4 prevents identifier-integrity drift that introduces hallucinated NCT identifiers or misclassified publication types.
Pattern N.1 prevents structural drift between peptide and small-molecule compound classes.

The discipline is the production-pipeline-anchored quality system. A clinician reading a Module 5 protocol can trust that every regulatory claim is Pattern AA-precise, every effect-direction claim is Pattern V-verified, every counseling beat is Pattern Z-calibrated, and every NCT identifier is Pattern AB-verified.

6.5 How to read a protocol — the reader’s framework

For a clinician new to the Pattern discipline, the reader’s framework:

Read Section 1 first to anchor indication scope. The protocol’s design-step lock means every downstream section reads through Section 1.
Read Section 11 (source citations) next to triangulate the evidence base. Pattern AA / AB.4 precision is at its densest in §11.
Read Section 10 (patient counseling beats) for the Pattern Z calibration. §10 is the clearest surface of the protocol’s framing discipline.
Read Sections 2 through 9 operationally when the specific operational question arises (selection, workup, initiation, maintenance, AE management, plateau / non-response, discontinuation, combination).
Read Section 12 (clinical decision tree) as the at-a-glance summary.
Consult the appendices when audit detail is needed (verification gate; Pattern discipline self-audit; byte-count audit and commit log).

6.6 Methodology cross-references

[[Synergy Editorial Framework]] v1.2 — voice, framing discipline, length expectations (§1.6), citation authority vs discovery methodology, the AA.marketing-claims convention (§1.2.1), the Z.injection-framing and Z.research-precision sub-pattern reframes (§1.4 loaded-vocabulary table).
[[AC2-26 – System Observations]] — the full Pattern catalog with provoking observations, operational anchors, cross-references, and dated discovery context.
[[Voice Profile – Dr. Jeff Gross MD]] — clinician-voice calibration that anchors §10 counseling beats and the protocol’s tonal register throughout.
/Internal/Module-5-Pipeline/pattern-z-calibration-anchor.md — the five verbatim-correct counseling-beat anchors.
[[Protocol Template]] — the structural authority every protocol mirrors.

§7 Cross-cutting clinical considerations

Section §7 covers four clinical considerations that cut across the per-canonical and adjunct protocols — phenotypes and decisions that recur in multiple protocols’ §1, §6, §8, §9, and §10 and benefit from a module-level synthesis. The full operational detail lives in each per-compound protocol; §7 of this index is the synthesis view.

7.1 Pre-conception planning across compounds

The clinical context. Reproductive-age female patients on canonical or adjunct therapy require structured pre-conception planning when pregnancy is the patient’s stated near-term goal. Pregnancy is a Section 8 hard discontinuation trigger across the GLP-1 RA class, the dual coagonist class, the triple coagonist class, the amylin class, the GLP-1 RA combination products (CagriSema, IcoSema), and the GHRH-axis adjunct compounds (tesamorelin, CJC-1295 / Ipamorelin). The decision is not whether to discontinue — discontinuation is the operational position — but when and how.

Pattern Z anchor 3 — research-state-leading framing. Every per-canonical protocol’s pregnancy section opens with the human-pregnancy-exposure research-state data (Parker 2025 pooled review PMID 40329607: pooled unplanned-pregnancy exposures from FDA- and EMA-submitted GLP-1 RA regulatory clinical trials — semaglutide, liraglutide, dulaglutide, class-related compounds — with incidence of congenital abnormalities appearing relatively low; sample size limited; prospective planned-pregnancy exposure data remains an active research direction). The research-state lead precedes the operational discontinuation algorithm.

Module-level discontinuation arithmetic by compound. The arithmetic is half-life-driven; the operational rule is approximately 5 half-lives for substantial clearance:

Compound class	Compound	Half-life	Approximate clearance time (~5 half-lives)	Pre-conception washout recommendation
GLP-1 RA daily	Liraglutide	~13 hours	~3 days	≥2 weeks pre-conception
GLP-1 RA weekly	Semaglutide	~7 days	~35 days	≥2 months pre-conception
GLP-1 RA / GIP dual weekly	Tirzepatide	~5 days	~25 days	≥2 months pre-conception
GLP-1 / GIP / glucagon triple weekly	Retatrutide (pre-approval)	~6 days	~30 days	≥2 months pre-conception (trial-protocol washout convention)
GLP-1 / glucagon dual weekly	Survodutide (pre-approval)	~6 days	~30 days	≥2 months pre-conception
Amylin analog weekly	Cagrilintide (pre-approval)	~7 days	~35 days	≥2 months pre-conception
Combination weekly	CagriSema (pre-approval)	semaglutide-anchored	~35 days	≥2 months pre-conception
Combination weekly	IcoSema (pre-approval)	icodec-anchored (~1 week)	~35 days	≥2 months pre-conception
Oral small-molecule daily	Orforglipron (pre-approval)	~29 hours	~6 days	≥2 weeks pre-conception (pharmacodynamic margin per protocol §8)
GHRH analog daily	Tesamorelin	~26–38 minutes (peptide); biological effect lasts hours	~1 day	≥1 week pre-conception (per cautionary practice)
GHRH analog weekly	CJC-1295 with DAC	~6–8 days	~35 days	≥2 months pre-conception
GHRP daily	Ipamorelin	~2 hours	~10 hours	≥3 days pre-conception (per cautionary practice)

Counseling-beat anchor. Every per-canonical protocol’s §10 carries the pre-conception counseling beat anchored at Pattern Z anchor 3. The patient question — “I want to get pregnant; what do I do about [compound]?” — is answered fact-based: state the compound’s half-life and washout arithmetic; state the discontinuation timing; state that the discontinuation is operational rather than evidence-of-teratogenicity (Parker 2025 reassuring early human signal; animal data supported the original Category-X-equivalent contraindication but does not always translate to human teratogenicity profile); state that pregnancy planning is shared-decision-making with the patient’s obstetric care.

Patient-population subset to flag. Patients on canonical therapy who become pregnant during therapy before pre-conception planning has occurred. The operational position is immediate discontinuation; the clinical question is the post-discontinuation surveillance posture — patient-decision-relevant data points include the Parker 2025 reassuring early signal, the compound’s half-life and clearance arithmetic, the patient’s gestational age at first exposure, and obstetric co-management. The protocols’ §10 carries the counseling beat for this scenario.

7.2 Pediatric obesity across compounds

The clinical context. Pediatric obesity (BMI at the 95th percentile or greater) and pediatric T2D are growing clinical phenotypes. Two compounds in the Module 5 portfolio carry pediatric FDA-approved-for-marketing-claims indications as of 2026-05-13:

Liraglutide (Victoza) — FDA-approved for marketing claims for pediatric T2D ≥10 years (Ellipse trial; label expansion 2019). The only FDA-approved-for-marketing-claims GLP-1 RA for pediatric T2D as of 2026-05-13.
Liraglutide (Saxenda) — FDA-approved for marketing claims for pediatric obesity ≥12 years (SCALE-Teens trial; label expansion 2020).
Semaglutide (Wegovy) — FDA-approved for marketing claims for adolescent chronic weight management ≥12 years (STEP-TEENS trial NCT04102189; label expansion 2022). Effect-size anchor: BMI reduction ~16.1% with semaglutide 2.4 mg vs ~+0.6% with placebo at 68 weeks.

Other Module 5 compounds (tirzepatide; retatrutide; survodutide; cagrilintide; CagriSema; IcoSema; orforglipron) do not have pediatric FDA-approved-for-marketing-claims indications as of 2026-05-13; pediatric trial programs are at varying stages of development.

Phenotype-specific considerations. Pediatric and adolescent obesity is mechanistically distinct from adult obesity in several dimensions that the per-canonical protocols address:

Growth-stage pharmacology. GH-axis adjuncts (tesamorelin, CJC-1295 / Ipamorelin) interact with growth-stage pharmacology in skeletally immature patients; these adjuncts are not used in pediatric patients without endocrinology co-management.
Appetite phenotype calibration. Adolescent appetite phenotype includes growth-mediated hyperphagia that is physiologic rather than pathologic; the M5.1 phenotype taxonomy specifies adolescent calibration.
Counseling-beat tonal calibration. Patient-counseling beats for adolescent patients and their parents differ from adult counseling beats in tonal register, framing of body-image considerations, and adherence calculus.

Module-level recommendation. For pediatric patients in scope (T2D ≥10 years; obesity ≥12 years), the relevant per-canonical protocol is the operational document. For pediatric obesity in patients <12 years, Module 5 protocol scope does not apply; clinical management routes through pediatric endocrinology and pediatric obesity-medicine specialty channels.

7.3 T2D + CV + CKD multi-condition phenotypes

The clinical context. A meaningful patient subset on canonical therapy carries multiple Module 5 indications simultaneously — T2D + established ASCVD + CKD + MASH + obesity all in the same patient. This polycondition phenotype is qualitatively different from the monocondition phenotype for compound-selection purposes.

The polycondition compound selection. Semaglutide is the single compound covering the broadest set of polycondition indications as of 2026-05-13:

T2D glycemic control (Ozempic 2017; Rybelsus 2019)
Chronic weight management (Wegovy 2021; HD 7.2 mg 2026)
CV risk reduction in established ASCVD (Ozempic for T2D + CVD 2020; Wegovy for BMI ≥27 + ASCVD without diabetes 2024)
MASH F2–F3 (Wegovy 2025)
CKD in T2D (Ozempic 2025)

For the polycondition phenotype patient with T2D + ASCVD + CKD + MASH + obesity, semaglutide is the operational first-line. Tirzepatide is competitive on T2D, CWM, and the HFpEF-with-obesity (SUMMIT) and OSA-with-obesity (SURMOUNT-OSA) extensions but does not have MASH or CKD-composite FDA-approved-for-marketing-claims indications.

Module-level recommendation. The polycondition phenotype is the highest-value compound-selection scenario for the decision-tree protocol; [[Module 5 – Phenotype-Guided Decision Tree Protocol]] §branch 9 (comorbidity-load branch) covers this explicitly. The polycondition phenotype is also where the protocol library’s structural homology pays off — a clinician managing the polycondition patient can read the semaglutide protocol’s §1 (six FDA-approved-for-marketing-claims indications) and §6 (AE management across the multi-condition surveillance burden) without needing to consult five separate compound documents.

7.4 Compounded vs FDA-approved decision framework

The clinical context. Compounded preparations of GLP-1 RAs, dual coagonists, amylin analogs, and adjunct peptides are real-world clinical options used by substantial patient populations. The 2022–2024 FDA-declared shortages of semaglutide and tirzepatide created a broad 503A and 503B compounding ecosystem. The October 2024 FDA shortage-list removal for tirzepatide narrowed the compounding pathway for that compound; the semaglutide compounding ecosystem has evolved similarly. Compounded preparations of pre-FDA-approval-for-marketing-claims compounds (retatrutide; survodutide; cagrilintide; CagriSema; IcoSema; orforglipron) have also emerged; the regulatory state varies by compound and changes over time.

Pattern Z anchors 1 + 2 — load-bearing across the protocol library. Every per-canonical protocol’s §10 carries the compounded-formulation counseling beat at Pattern Z anchor 1 (operational characteristics) and anchor 2 (compounded-vs-FDA-approved patient question). The anchors frame compounded preparations as real-world clinical options used by substantial patient populations; the operational differences from FDA-approved formulations (format — lyophilized vial requiring reconstitution vs pre-filled pen; manufacturing oversight pathway — compounding regulations vs FDA NDA; storage — reconstituted at 2–8 °C × 28 days for many semaglutide compounded preparations vs ~28-day room-temperature stability for Novo pen post-first-use; excipient profile per pharmacy specification) are framed as factual scope, not deficit framing.

Module-level decision framework. The clinician’s evaluation across compounds:

Is the compound FDA-approved for marketing claims for the indication and currently in commercial supply? If yes, the FDA-approved formulation is the operational first-line. If no (compound is pre-FDA-approval-for-marketing-claims, or compound is in FDA-declared shortage), the compounded-formulation conversation becomes operationally meaningful.
Is the compounding pharmacy operating with documented quality criteria? Sterility testing per USP <797> (sterile compounding) and <800> (hazardous drugs) standards; certificate of analysis per batch (peptide content, purity, residual solvents, endotoxin); cold-chain shipping; state-licensure (503A) or FDA-registration (503B) verification; salt-form documentation (where applicable — e.g., tirzepatide base vs tirzepatide sodium).
Is the patient adequately informed about the operational differences? Format and reconstitution; storage; cost; insurance-coverage state; cold-chain handling at home; the regulatory pathway difference between FDA-approved and compounded preparations.
Is the clinical decision shared with the patient with full Pattern Z fact-based framing? Anchor 2 verbatim: “Compounded [compound] is a real clinical option used by many patients. The operational differences from [FDA-approved brand] are real — different format that requires reconstitution, different oversight pathway, different storage. If you’re considering it, let’s review the specific compounding pharmacy’s quality practices — sterility testing, certificate of analysis, accreditation — and walk through reconstitution training together. That’s how the decision gets made well.”

Module-level recommendation. The compounded-vs-FDA-approved decision is the most recurring patient-counseling conversation in Module 5 clinical practice. Every per-canonical protocol’s §10 carries the verbatim-anchor-compliant counseling beat for the compound’s specific regulatory state at the protocol’s last-updated date. The protocol’s regulatory-state-specific framing changes as the underlying state changes (shortage list updates; FDA enforcement actions; litigation outcomes); protocols are updated at protocol-revision cadence to reflect current state.

7.5 Additional cross-cutting considerations — brief synthesis

The four primary cross-cutting considerations above are the most recurring across the protocols. Four additional cross-cutting considerations are addressed at the per-canonical protocol level but benefit from a brief module-level synthesis:

GI side-effect management across the class. Nausea, vomiting, constipation, diarrhea, abdominal pain — the GLP-1 RA class-characteristic GI AE profile. Class-wide management algorithms (slow titration; antiemetic adjuncts; hydration support; dietary modifications). Cross-compound variation (cagrilintide may attenuate GLP-1-RA-mediated GI AE in CagriSema; tirzepatide GI AE profile vs semaglutide GI AE profile is mechanism-distinct but operationally similar). Every per-canonical protocol’s §6 carries the GI-class AE management algorithm specific to that compound.
Pancreatitis surveillance. The GLP-1 RA class carries a labeled pancreatitis precaution (post-marketing signal; FDA labeled cautionary use). The class-level surveillance is symptomatic monitoring; routine lipase / amylase monitoring is not class-recommended. Every per-canonical protocol’s §6 addresses pancreatitis surveillance specific to the compound.
Thyroid C-cell surveillance. FDA boxed warning across the GLP-1 RA class for medullary thyroid carcinoma (MTC) and MEN-2 — based on rodent C-cell tumorigenicity signal; human MTC signal is debated but the boxed-warning-mandated contraindication is absolute (personal or family history of MTC, MEN-2). Routine calcitonin monitoring is not class-recommended; the surveillance is contraindication-screen at baseline and symptomatic monitoring during therapy.
NAION ophthalmologic class-differentiation. Lawrenson 2025 PMID 40383360 documented ION (with NAION as the primary clinical subtype) signal-presence for semaglutide and signal-absence for tirzepatide at the same analytical threshold. The class-differentiation finding is hypothesis-generating, not class-wide. Patients with relevant ophthalmologic risk factors (small disc-to-cup ratio; prior NAION; nocturnal hypotension; obstructive sleep apnea) may have decision-relevant compound-selection considerations; the relevant per-canonical protocols’ §6.5 and §10 carry the precision-framed counseling beats.

§8 Module 5 lesson cross-reference

8.1 The lesson library

The Module 5 lessons at /Peptide Projects/Pepteon Academy/m5-content/ are the clinical-education layer (Layer 1 per §1.4 above). The lessons are written for learning; the protocols are written for operational reference. The lesson library:

M5.1 — Obesity Pathophysiology — Hormonal, Metabolic & Neural Drivers (~2,421 words)
M5.2 — GLP-1 Receptor Agonists — Semaglutide Deep Dive (~5,856 words)
M5.3 — Tirzepatide (Mounjaro/Zepbound) — Dual GIP/GLP-1 Mechanism (~1,663 words)
M5.4 — Liraglutide, Triagonists & Combo-Products — Module 5 Comparator Landscape (~4,836 words)
M5.5 — Tesamorelin + AOD-9604 — Targeted Visceral & Adipose Fat Protocols (~2,657 words)
M5.6 — Lean Mass Preservation — CJC/Ipamorelin + MOTS-c During Weight Loss (~1,898 words)
M5.7 — Post-Weight-Loss Skin Laxity — GHK-Cu Protocols (~1,147 words)
M5.8 — Patient Titration Schedules, Side Effect Management & Dose Optimization (~2,253 words)
M5.9 — Lab Panels — HbA1c, Lipids, Insulin, Leptin, Body Composition (~809 words)
M5.10 — Case Study — 50+ lb Loss with GLP-1 + Muscle Preservation Stack (~1,061 words)
M5 Quiz — Module 5 Quiz (~4,395 words)
M5 Sources — Sources & References (~1,365 words)

Cumulative lesson length: ~28,000 words across 10 lessons + quiz + sources, with 76 evidence-table rows and 194 unique PMIDs.

8.2 Lesson-to-protocol cross-reference table

For clinicians who want the clinical-education context first (the lesson-first reading order):

Lesson	Protocol relevance	When to read together
M5.1 Pathophysiology	Anchors the phenotype taxonomy used throughout every per-canonical protocol’s §1 indication scope and §1.3 phenotype-targeting taxonomy	Read M5.1 before reading any per-canonical protocol §1 to anchor the phenotype framework
M5.2 Semaglutide Deep Dive	Cross-references [[Semaglutide Protocol]] §1 through §12 and [[Module 5 – Phenotype-Guided Decision Tree Protocol]] branch points 1 (indication-category mapping), 4 (magnitude-of-effect), 5 (indication-specific approval state)	Read together when learning the semaglutide pharmacology and indication scope
M5.3 Tirzepatide	Cross-references [[Tirzepatide Protocol]] §1 through §12 and the decision-tree §branch 6 (route + cadence), §branch 7 (AE-driven, NAION class-differentiation), §branch 11 (compounded-vs-FDA-approved)	Read together when learning dual coagonist pharmacology
M5.4 Liraglutide + Triagonists + Combos	Cross-references [[Liraglutide Protocol]], [[Retatrutide Protocol]], [[Survodutide Protocol]], [[CagriSema Protocol]], [[IcoSema Protocol]]	Read as the comparator-landscape orientation before the pre-approval canonicals
M5.5 Tesamorelin + AOD-9604	Cross-references [[Tesamorelin + AOD-9604 – Visceral Fat Adjunct Protocol]]	Read together when the visceral-fat-dominant phenotype enters the patient encounter
M5.6 Lean Mass Preservation	Cross-references [[CJC-1295 + Ipamorelin + MOTS-c – Lean Mass Preservation Stack Protocol]]	Read together when the lean-mass-loss concern enters the patient encounter
M5.7 GHK-Cu Skin Laxity	Cross-references [[GHK-Cu – Post-Weight-Loss Skin Laxity Protocol]]	Read together when the post-weight-loss skin-laxity complaint enters the patient encounter
M5.8 Titration + AE Management	Cross-references every per-canonical protocol’s §4 (initiation), §5 (maintenance), §6 (AE management), §7 (plateau / non-response)	Read as a class-level orientation to titration and AE management before reading any per-canonical §4–§7
M5.9 Lab Panels	Cross-references every per-canonical protocol’s §3 (pre-treatment workup) and §5 (maintenance monitoring cadence)	Read as the class-level orientation to lab-panel framework before reading any per-canonical §3 and §5
M5.10 Case Study	Cross-references [[Module 5 – Phenotype-Guided Decision Tree Protocol]] §branch points (the case study operationalizes the decision tree on a worked patient) plus every per-canonical protocol’s §10 (counseling beats)	Read as the integration-layer case study after the per-canonical protocols and the decision tree

8.3 Recommended lesson-first reading order for clinicians who prefer the clinical-education layer first

For clinicians who prefer the lesson-first orientation (lesson layer before protocol layer):

M5.1 Pathophysiology — anchor the phenotype framework
M5.2 Semaglutide Deep Dive — the structural-exemplar mechanism + indication scope
M5.3 Tirzepatide — the dual coagonist mechanism extension
M5.4 Liraglutide + Triagonists + Combos — the comparator-landscape orientation
M5.5 / M5.6 / M5.7 — the adjunct-compound-family orientations (in the order they apply to the clinician’s practice)
M5.8 Titration + AE Management — the class-level operational framework
M5.9 Lab Panels — the class-level lab-panel framework
M5.10 Case Study — the integration-layer case study

After the lesson layer, route to this index and the per-canonical / adjunct / decision-tree protocols per §1.3 protocol-first reading order.

8.4 Why both layers exist

The lessons teach the framework; the protocols operationalize the framework. The clinician learns the pathophysiology, mechanism, and indication scope through the lessons; the clinician implements the operational decisions in patient encounters through the protocols. The two layers are designed to interlock — the lessons cite the same primary sources the protocols cite (the 194 unique PMIDs in M5 Sources are a substantial subset of the citations in the per-canonical protocols’ §11). A clinician using both layers benefits from the framework-and-operational pairing; a clinician using only one layer can succeed but encounters either a learning-layer-without-operational-detail gap (lessons only) or an operational-layer-without-framework gap (protocols only).

§9 Source citations + further reading

9.1 High-yield Tier 1 citations across the module

The full source citations for every load-bearing claim in this index live in the relevant per-canonical and adjunct protocols’ §11 plus the canonical reference documents’ Bibliography files. The high-yield Tier 1 citations summarized below anchor the module-level claims this index makes:

GLP-1 RA class — semaglutide. SUSTAIN-6 (CVOT in T2D + CVD; PMID 27295427); SUSTAIN-7 (head-to-head vs dulaglutide; PMID 29397376); STEP-1 (CWM; PMID 33567185); STEP-2 (CWM + T2D; PMID 33667417); STEP-TEENS (adolescent CWM; PMID 36322838); SELECT (CWM + CV in non-diabetic ASCVD; PMID 38078102); ESSENCE (MASH F2–F3; sponsor topline 2025); FLOW (CKD in T2D; PMID 38785307); STEP UP (Wegovy HD 7.2 mg; sponsor topline 2025); STEP-HFpEF (PMID 37579119); Parker 2025 pooled pregnancy review (PMID 40329607).

GLP-1 / GIP dual coagonist — tirzepatide. Coskun 2018 Mol Metab mechanism (PMID 30473097); SURPASS-2 head-to-head vs semaglutide in T2D (PMID 34170647); SURMOUNT-1 (CWM; PMID 35658024); SURMOUNT-5 head-to-head vs semaglutide in CWM (PMID 40353578); SURMOUNT-OSA (PMID 38861701); SUMMIT (HFpEF; PMID 39555826); SYNERGY-NASH Phase 2 (PMID 38856224); Lawrenson 2025 NAION class-differentiation (PMID 40383360).

Triple coagonist — retatrutide. TRIUMPH-1 Phase 2 obesity (Jastreboff NEJM 2023; PMID 37354645); TRIUMPH-4 sponsor topline December 2025.

Glucagon / GLP-1 dual coagonist — survodutide. Le Roux 2024 Phase 2 obesity (PMID 38446694); SYNCHRONIZE-1 / -2 obesity Phase 3; SYNCHRONIZE-NASH MASH Phase 3 (NCT06632327).

GLP-1 RA daily — liraglutide. LEAD program (T2D); SCALE-Obesity-and-Prediabetes (CWM; PMID 26132939); LEADER (CV; PMID 27295427); Ellipse (pediatric T2D; PMID 31185166); SCALE-Teens (pediatric obesity; PMID 32320557).

Amylin analog — cagrilintide. Lacefield 2024; Frias 2023 Phase 2 monotherapy.

Combination products — CagriSema and IcoSema. REDEFINE-1 obesity sponsor topline 2025; REDEFINE-2 obesity-with-T2D sponsor topline 2025; COMBINE-1 vs basal-bolus icodec sponsor topline.

Small-molecule oral non-peptide GLP-1R agonist — orforglipron. ACHIEVE-1 T2D sponsor topline 2025; ATTAIN-1 CWM sponsor topline 2025; Pratt et al Nature 2024 mechanism / non-peptide structure characterization.

Tesamorelin + AOD-9604 visceral fat. Falutz program HIV lipodystrophy (Tesamorelin FDA approval 2010); Stanley JAMA 2014 non-HIV obesity with MASLD (PMID 25038357); Tesamorelin Body Composition Meta-Analysis (PMID 41545261); AOD-9604 development literature (PMID 11146367; PMID 11713213; PMID 15134286).

CJC-1295 + Ipamorelin + MOTS-c lean mass. CJC-1295 discovery and pharmacology (PMID 15817669; PMID 19386527; PMID 17018654); Ipamorelin GHRP-class characterization; MOTS-c mechanism (Lee 2015 Cell Metab PMID 25738459; Reynolds 2021 FASEB J PMID 33473109; PMID 36677050; PMID 33473109).

GHK-Cu skin laxity. Pickart 1973 (original GHK characterization in human plasma); Maquart 1988, 1993 (fibroblast collagen synthesis); animal wound-healing (PMID 28370978; PMID 27517151); gene-expression and tissue-remodeling (PMID 18644225; PMID 25302294; PMID 35083444; PMID 39963574).

9.2 Methodology references

[[AC2-26 – System Observations]] — the full Pattern catalog
[[Synergy Editorial Framework]] v1.2 — voice, framing, length, citation authority, Pattern AA.marketing-claims convention, Pattern Z.injection-framing, Pattern Z.research-precision
[[Voice Profile – Dr. Jeff Gross MD]] — clinician-voice calibration
[[Protocol Template]] — the structural authority
/Internal/Module-5-Pipeline/pattern-z-calibration-anchor.md — the five verbatim-correct counseling-beat anchors

9.3 Further reading — module-adjacent

/obsidian-peptides/Peptides/ — the canonical reference documents (Layer 3 deep-evidence layer) for every Module 5 compound
/Process/[Compound]/ — the production iteration log for each canonical
/Peptide Projects/Pepteon Academy/m5-content/ — the Module 5 lesson library (Layer 1 clinical-education layer)
/obsidian-peptides/Patient Intelligence/Module 5 - Weight Loss & Metabolic/ — patient-question taxonomy and counseling exemplars
/obsidian-peptides/Evidence Library/ — FDA labels and regulatory documents anchoring Pattern AA.marketing-claims precision throughout

§10 Version + update history

10.1 This index — version state

Index version: v2.0 (comprehensive Wave-3-complete refresh; supersedes v1.0 Commit 5/5 cross-link fix-up that was produced while sibling Wave 3 protocols were still in flight — race condition led to initial cross-link fix-up in Commit 5/5 but v2 is the comprehensive refresh now that all 13 protocols exist)
Document type: navigation and orientation index (top-level wayfinder, not a per-compound protocol)
Last-updated: 2026-05-13 (end-of-day session-state capture)
Status: production draft — awaiting Dr. Gross verification gate
Owners: Daria Pechaiko (production); Dr. Jeff Gross MD (clinical verification gate)
Audience: practicing clinicians (MD / NP / PA) starting to use the Module 5 protocol library
Reading-time target: 30-minute orientation read + ongoing reference use

v2 refresh scope (2026-05-13):

§2 Portfolio table — refreshed with Pattern AA.marketing-claims precision at every regulatory-state claim; IcoSema patched to dual-jurisdiction precision (EMA-approved as Kyinsu, EC marketing authorization 24 November 2025; pre-FDA-approval-for-marketing-claims in the US); Liraglutide patched to include Xultophy 100/3.6 fixed-ratio combination indication and multiple generic ANDAs 2024–2025; Semaglutide patched to include precise Wegovy HD 7.2 mg approval date (March 19, 2026 via Commissioner’s National Priority Voucher Program), oral Wegovy 25 mg (OASIS program, August 2025), and SOUL CV oral semaglutide trial; Tirzepatide row carried forward (no drift).
§3 Per-canonical summaries — refreshed; IcoSema (§3.8) and Liraglutide (§3.5) patched with the same regulatory-state precision; other seven canonicals carried forward (no drift).
§4 Adjunct summaries — carried forward (no drift).
§5 Decision Tree summary — carried forward (10 phenotype axes confirmed accurate: Axis 1 obesity type / Axis 2 T2D status / Axis 3 CV history / Axis 4 kidney status / Axis 5 hepatic status / Axis 6 pre-conception planning / Axis 7 age-stage / Axis 8 route preference / Axis 9 cost-access / Axis 10 body-composition concern).
§6 Methodology — Pattern catalog reference expanded to include all five sub-patterns codified during the Module 5 production cycle: V.metric-axis, V.estimand-axis, AA.marketing-claims, Z.injection-framing, Z.research-precision; Pattern V section expanded with the V.metric-axis (per-arm vs between-group disclosure) and V.estimand-axis (treatment-policy vs treatment-regimen vs efficacy estimand disclosure) sub-pattern treatments; Editorial Framework v1.2 §1.2.1 cross-reference confirmed.
§7 Cross-cutting — pre-conception washout table verified accurate across all 12 compounds (half-life arithmetic anchored to canonical pharmacokinetic data; ~5-half-life clearance convention).
§8 Lesson cross-reference — M5.X → protocol map confirmed accurate; lesson-script production state updated (all 10 M5.1–M5.10 narration scripts v3 produced 2026-05-13).
§10 Version + update history — refreshed to v2; Wave 1 + 2 + 3 completion sequence locked; Dr. Gross M5.1 NotebookLM audio feedback iteration 1 incorporation captured; script reformat (narration-block / production-note / on-screen-text separation) documented.

10.2 Pattern catalog state as of this version

The Pattern catalog this index references is the AC2-26 System Observations v2.4.2-compatible state as of 2026-05-13, with five sub-patterns codified during the Module 5 production cycle:

Pattern R (anti-deficit-leading framing)
Pattern R.1 (sentence-level anti-deficit-leading)
Pattern R.2 (design-step indication-scope-lock enforcement)
Pattern V (direction-of-effect verification) with two new sub-patterns codified 2026-05-13 (Module 5 Stage 4 Sub-Audit B):
- Pattern V.metric-axis — per-arm absolute change vs between-group treatment effect disclosure
- Pattern V.estimand-axis — treatment-policy vs treatment-regimen vs efficacy estimand disclosure (sibling sub-pattern; applies to dual-estimand trials such as SURMOUNT-1 TR-vs-efficacy, OASIS 4 TP-vs-adherent, STEP UP regulatory-summary-vs-trial-primary)
Pattern W (cross-section consistency)
Pattern Z (steering-direction test) with two sub-patterns codified 2026-05-13 (Dr. Gross M5.1 NotebookLM audio feedback):
- Pattern Z.injection-framing — self-injection as routine clinical skill, not daunting barrier; bias-vocabulary “scary / daunting / intimidating” applied to self-injection is a Pattern Z violation
- Pattern Z.research-precision — bias-vocabulary “highly experimental / fringe / speculative / untested” applied to investigational compounds or off-label uses is a Pattern Z violation; replace with research-state precision (trial names, magnitudes, NCT identifiers, readout state, publication state)
Pattern AA (regulatory-state precision) with one sub-pattern codified 2026-05-13 (Editorial Framework §1.2.1):
- Pattern AA.marketing-claims — “FDA-approved for marketing claims for [indication X]” load-bearing precision; approval-for-marketing-claims is indication-specific (not drug-specific); off-label use of an FDA-approved-for-marketing-claims drug remains use of an FDA-approved drug
Pattern AB.1 (NCT-identifier-to-content internal-consistency standing scan)
Pattern AB.2 (sponsor-to-trial linkage standing scan)
Pattern AB.4 (publication-type accuracy standing scan)
Pattern N.1 (small-molecule-vs-peptide path enforcement)

The five new sub-patterns (V.metric-axis, V.estimand-axis, AA.marketing-claims, Z.injection-framing, Z.research-precision) reflect the cumulative methodological discoveries of the Module 5 production cycle and are cross-referenced in [[Synergy Editorial Framework]] v1.2 (§1.2.1 AA.marketing-claims clarified nuance; §1.4 loaded-vocabulary expansion for the two Z sub-patterns) and in [[AC2-26 – System Observations]] (Pattern V.metric-axis + V.estimand-axis sub-pattern entries with discovery-context citations).

10.3 Wave history — the protocol library production sequence

The Module 5 protocol library was produced in three production waves over April–May 2026, all completed as of end-of-day 2026-05-13:

Wave 1 (lead exemplars, April–May 2026). Three canonicals produced as the calibration baseline subsequent canonicals mirror:
- [[Semaglutide Protocol]] — Wave 1 lead exemplar; the structural template every subsequent protocol mirrors
- [[Tirzepatide Protocol]] — Wave 1; the dual-coagonist mechanism exemplar; the NAION class-differentiation finding integration
- [[Retatrutide Protocol]] — Wave 1; the triple-coagonist mechanism exemplar; the pre-FDA-approval-for-marketing-claims framing template
Wave 2 (extension to combinations and amylin, April–May 2026). Four canonicals extending the calibration:
- [[Survodutide Protocol]] — Wave 2; the glucagon-axis-distinct dual coagonist
- [[Cagrilintide Protocol]] — Wave 2; the amylin-class mechanism precision
- [[CagriSema Protocol]] — Wave 2; the registration-evaluated amylin + GLP-1 RA combination
- [[IcoSema Protocol]] — Wave 2; the basal-insulin + GLP-1 RA combination; dual-jurisdiction regulatory framing (EMA-approved as Kyinsu, EC marketing authorization 24 November 2025; pre-FDA-approval in the US)
Wave 3 (completion + integration, May 2026). The remaining canonicals plus the adjunct family plus the decision-tree plus this index:
- [[Liraglutide Protocol]] — Wave 3 #1; the class-foundational GLP-1 RA with pediatric T2D ≥10 years indication uniqueness and Xultophy fixed-ratio combination coverage
- [[Orforglipron Protocol]] — Wave 3 #2; the small-molecule non-peptide oral path (Pattern N.1 enforcement exemplar)
- [[Tesamorelin + AOD-9604 – Visceral Fat Adjunct Protocol]] — Wave 3 #3 family (adjunct visceral-fat)
- [[CJC-1295 + Ipamorelin + MOTS-c – Lean Mass Preservation Stack Protocol]] — Wave 3 #3 family (adjunct lean-mass)
- [[GHK-Cu – Post-Weight-Loss Skin Laxity Protocol]] — Wave 3 #3 family (adjunct skin-laxity)
- [[Module 5 – Phenotype-Guided Decision Tree Protocol]] — Wave 3 #4 (the compound-selection algorithm; 10 phenotype axes)
- This index — Wave 3 #5 (the top-level wayfinder; the document you are reading; v1.0 produced in initial Wave 3 cycle with Commit 5/5 cross-link fix-up; v2 comprehensive refresh end-of-day 2026-05-13 now that all 13 protocols exist + Dr. Gross iteration 1 incorporated + 5 methodology sub-patterns codified + script reformat applied across the lesson library + all 10 M5.1–M5.10 narration scripts v3 produced)

10.3.1 End-of-day 2026-05-13 production state — comprehensive snapshot

The Module 5 production cycle reached the following terminal state as of end-of-day 2026-05-13:

Protocol library — 13 documents at /obsidian-peptides/Protocols/:

Semaglutide Protocol (Wave 1; ~1,900 lines; six FDA-approved-for-marketing-claims indications)
Tirzepatide Protocol (Wave 1; dual GIP/GLP-1; three FDA-approved indications)
Retatrutide Protocol (Wave 1; triple coagonist; pre-FDA-approval)
Survodutide Protocol (Wave 2; glucagon + GLP-1; pre-FDA-approval)
Cagrilintide Protocol (Wave 2; amylin analog; pre-FDA-approval-as-monotherapy)
CagriSema Protocol (Wave 2; cagrilintide + semaglutide; pre-FDA-approval)
IcoSema Protocol (Wave 2; insulin icodec + semaglutide; EMA-approved as Kyinsu 2025-11-24; pre-FDA)
Liraglutide Protocol (Wave 3; daily SC GLP-1 RA; five FDA-approved indications + Xultophy combination)
Orforglipron Protocol (Wave 3; small-molecule non-peptide oral GLP-1R agonist; pre-FDA-approval; Pattern N.1)
Tesamorelin + AOD-9604 – Visceral Fat Adjunct Protocol (Wave 3 adjunct; tesamorelin FDA-approved for HIV lipodystrophy; AOD-9604 503A)
CJC-1295 + Ipamorelin + MOTS-c – Lean Mass Preservation Stack Protocol (Wave 3 adjunct; all three 503A / investigational)
GHK-Cu – Post-Weight-Loss Skin Laxity Protocol (Wave 3 adjunct; cosmetic-grade + 503A)
Module 5 – Phenotype-Guided Decision Tree Protocol (Wave 3; 10-axis compound-selection algorithm)

Master Protocol Index (this document) — v2 comprehensive refresh.

Lesson library — 10 lessons at /Peptide Projects/Pepteon Academy/m5-content/:

M5.1 Obesity Pathophysiology — v3 markdown + v3 PDF + v3 narration script
M5.2 GLP-1 RAs Semaglutide Deep Dive — v3 markdown + v3 PDF + v3 narration script
M5.3 Tirzepatide Dual GIP/GLP-1 — v3 markdown + v3 PDF + v3 narration script
M5.4 Liraglutide / Triagonists / Combos — v3 markdown + v3 PDF + v3 narration script
M5.5 Tesamorelin + AOD-9604 — v3 markdown + v3 PDF + v3 narration script
M5.6 Lean Mass Preservation — v3 markdown + v3 PDF + v3 narration script
M5.7 GHK-Cu Skin Laxity — v3 markdown + v3 PDF + v3 narration script
M5.8 Patient Titration / AE Management / Dose Optimization — v3 markdown + v3 PDF + v3 narration script
M5.9 Lab Panels — v3 markdown + v3 PDF + v3 narration script
M5.10 Case Study (50+ lb Loss with GLP-1 + Muscle Preservation Stack) — v3 markdown + v3 PDF + v3 narration script

All 10 narration scripts produced 2026-05-13. Script reformat (narration-block / production-note / on-screen-text separation) applied across the lesson library.

Methodology state:

[[Synergy Editorial Framework]] v1.2 (last patched 2026-05-13): §1.2.1 AA.marketing-claims clarified nuance + §1.4 loaded-vocabulary expansion for Z.injection-framing + Z.research-precision
[[AC2-26 – System Observations]] v2.4.2-compatible state: Pattern V.metric-axis + V.estimand-axis sub-pattern entries added during Module 5 Stage 4 Sub-Audit B (2026-05-13)
Dr. Gross M5.1 NotebookLM audio feedback iteration 1 incorporated — codified as Pattern Z.injection-framing and Pattern Z.research-precision sub-patterns
Five methodology sub-patterns codified end-of-day 2026-05-13: V.metric-axis, V.estimand-axis, AA.marketing-claims, Z.injection-framing, Z.research-precision

Canonical reference library state: v1.0-final canonicals at /obsidian-peptides/Peptides/[Compound].md for all 12 compounds in scope (semaglutide is the calibration baseline at ~1,930 verified PMIDs; other 11 canonicals are operationally complete).

10.4 Anticipated update cadence

The Module 5 protocol library is anchored at the GLP-1-receptor pharmacology era as of 2026-05-13. The library updates at the following cadence:

FDA-approval-state changes (new indication approvals; label expansions; new compound approvals — e.g., when retatrutide / survodutide / CagriSema / IcoSema / orforglipron transition from pre-approval to FDA-approved-for-marketing-claims state) trigger relevant per-canonical protocol revisions and a corresponding update to this index’s §2 table and §3 summaries.
Phase 3 trial readouts (sponsor topline → peer-reviewed publication transitions) trigger Pattern AB.4 publication-type updates in the relevant per-canonical protocol’s §11 and corresponding propagation to §1 indication scope where regulatory-state-determinative.
Pattern catalog additions (new sub-patterns; new cross-cutting observations from Dr. Gross verification cycles or other Pattern-discovery events) trigger updates to this index’s §6.
New compounds entering Module 5 scope (Phase 3 readout positive; FDA approval anticipated within 12 months) trigger new per-canonical protocol production and corresponding index integration.

10.5 Verification gate

This index passes the four-step verification gate before publication, per [[Protocol Template]] Appendix A. The four steps:

Structural completeness check — all ten sections present; all wikilinks resolve; all referenced protocols and methodology documents exist
Pattern discipline self-audit — Pattern R / R.1 / R.2 / V / W / Z (+ sub-patterns) / AA (+ AA.marketing-claims) / AB.1 / AB.2 / AB.4 / N.1 enforcement checked at index scope
Cross-protocol consistency audit — the index’s per-canonical and adjunct summaries are consistent with the source protocols’ §1 indication scope
Clinical verification gate — Dr. Gross review for clinician-voice calibration, Pattern Z calibration anchor compliance, and indication-scope accuracy

10.6 Acknowledgments and clinical-verification authority

This index was produced by the Pepteon Academy production pipeline under the structural authority of the Protocol Template v1.0 and the methodological authority of the AC2-26 System Observations and Synergy Editorial Framework v1.2. Clinical-verification authority resides with Dr. Jeff Gross MD; this document is in production-draft state awaiting that verification gate.

The Module 5 protocol library — nine canonicals + three adjunct compound families + one decision-tree protocol + this index — is intended as a clinician-facing reference framework for peptide and small-molecule therapeutics in weight loss, body composition, and metabolic disease. The framework’s claim is structural and methodological rigor (Pattern discipline; verification gates; primary-source anchoring; verbatim-anchor counseling-beat calibration). The framework does not substitute for clinician judgment in the individual patient encounter; the per-compound protocols, the decision-tree protocol, and this index present what the published research shows and how the trial-program evidence translates into operational clinical decisions. Clinical positioning for individual patients is the responsibility of the clinician using their professional judgment in the context of the patient and their specific clinical situation.

End of Module 5 — Master Protocol Index v2.0 (comprehensive Wave-3-complete refresh end-of-day 2026-05-13).

For navigation back to the per-canonical and adjunct protocols, use the wikilinks throughout. For the operational compound-selection algorithm, route to [[Module 5 – Phenotype-Guided Decision Tree Protocol]]. For the deep-evidence layer, route to /obsidian-peptides/Peptides/[Compound].md. For the clinical-education layer, route to /Peptide Projects/Pepteon Academy/m5-content/[Lesson].md.

Module 5 – Master Protocol Index